1 **Title:**

2 **A rapid, facile, and economical method for the isolation of ribosomes and**

3 **translational machinery for structural and functional studies**

4

5 **Authors:** Jessey Erath[1], Danielle Kemper [1], Elisha Mugo[1], Alex Jacoby[1], Elizabeth

6 Valenzuela[4], Courtney F. Jungers[1], Wandy L. Beatty[2], Yaser Hashem[3], Marko

7 Jovanovic[4], Sergej Djuranovic[1#], Slavica Pavlovic Djuranovic[1#]

8

9

10 **Affiliations**

11 [1]Department of Cell Biology and Physiology, Washington University School of Medicine,

12 Saint Louis, MO, USA.

13 [2]Department of Molecular Microbiology, Washington University School of Medicine,

14 Saint Louis, MO, USA.

15 [3]INSERM U1212 Acides nucléiques: Régulations Naturelle et Artificielle (ARNA), Institut

16 Européen de Chimie et Biologie, Université de Bordeaux, Pessac 33607, France

17 [4]Department of Biological Sciences, Columbia University, New York, NY, USA.

18 [#]correspondence to: spavlov@wustl.edu and sergej.djuranovic@wustl.edu

19

20

21

22

23

24

25

26

27

28

Short abstract

Ribosomes are essential RNA-protein complexes involved in protein synthesis and quality control. Traditional methods for ribosome isolation are labor intensive, expensive, and require substantial biological material. In contrast, our new method, RAPPL (RNA Affinity Purification using Poly-Lysine), offers a rapid, simple, and cost-effective alternative. This method enriches ribosomes and associated factors from various species and sample types, including cell lysates, whole cells, organs, and whole organisms, and is compatible with traditional isolation techniques. Here, we use RAPPL to facilitate the rapid isolation, functional screening, and structural analysis of ribosomes with associated factors. We demonstrate ribosome-associated resistance mechanisms from patient uropathogenic *Escherichia coli* samples and generate a 2.7Å cryoEM structure of ribosomes from *Cryptococcus neoformans*. By significantly reducing the amount of the starting biological material and the time required for isolation, the RAPPL approach improves the study of ribosomal function, interactions, and antibiotic resistance, providing a versatile platform for academic, clinical, and industrial research on ribosomes.

Long abstract

Ribosomes are macromolecular RNA-protein complexes that constitute the central machinery responsible for protein synthesis and quality control in the cell. Ribosomes also serve as a hub for multiple non-ribosomal proteins and RNAs that control protein synthesis. However, the purification of ribosomes and associated factors for functional and structural studies requires a large amount of starting biological material and a tedious workflow. Current methods are challenging as they combine ultracentrifugation, the use of sucrose cushions or gradients, expensive equipment, and multiple hours to days of work. Here, we present a rapid, facile, and cost-effective method to isolate ribosomes from *in vivo* or *in vitro* samples for functional and structural studies using single-step enrichment on magnetic beads – RAPPL (RNA Affinity Purification using Poly-Lysine). Using mass spectrometry and western blot analyses, we show that poly-lysine coated beads incubated with *E. coli* and HEK-293 cell lysates enrich specifically for ribosomes and ribosome-associated factors. We demonstrate the ability of RAPPL to isolate ribosomes and translation-associated factors from limited material quantities, as well as a wide variety of biological samples: cell lysates, cells, organs, and whole organisms. Using RAPPL, we characterized and visualized the different effects of various drugs and translation inhibitors on protein synthesis. Our method is compatible with traditional ribosome isolation. It can be used to purify specific complexes from fractions of sucrose gradients or in tandem affinity purifications for ribosome-associated factors. Ribosomes isolated using RAPPL are functionally active and can be used for rapid screening and *in vitro* characterization of ribosome antibiotic resistance. Lastly, we demonstrate the structural applications of RAPPL by purifying and solving the 2.7Å cryo-EM structure of ribosomes from the *Cryptococcus neoformans*, an encapsulated yeast causing cryptococcosis. Ribosomes and translational machinery purified with this method are suitable for subsequent functional or structural analyses and provide a solid foundation for researchers to carry out further applications – academic, clinical, or industrial – on ribosomes.

80

Main

As macromolecular RNA-protein complexes essential to the process of mRNA translation and quality control (*1-6*), ribosomes are highly conserved yet contain intrinsic diversity (*7-17*). The deconvolution of ribosome function and activity can provide insights into mechanisms of protein synthesis and quality control, as well as the state of a cell or organism at various times in its life cycle or differing growth conditions.

Methods have been developed to study ribosome-associated gene expression at the translation level - mainly ribosome purification by sucrose cushion or polysome profiling by sucrose gradients. Each method provided significant advancements to structural and functional studies of the mechanism of protein synthesis, gene expression control at the mRNA level, and quality control at the ribosome, mRNA, and nascent polypeptide levels. Although these methodologies offer valuable insights, as mentioned earlier, they are unsuitable for all material types, particularly those in low abundance. Purified ribosomes and translation-associated components end up in concentrated sucrose solutions, making downstream functional and structural applications cumbersome. Further purification and concentration steps usually result in additional loss of valuable material. Sucrose cushion and gradient purifications also require specialized equipment (ultracentrifuge, rotors, and fractionators) that can be cost-prohibitive for some labs and require significant time for proper separation. Due to lengthy procedures, these methods also require additional foresight and care regarding processes that could influence the chemical or biological stability of the material, oxidation status, and temperature control over long periods of time.

The interaction and coordination of cationic amino acids and anionic nucleic acid phosphate backbone have been well studied (*18*). On two occasions, monolithic anion exchange chromatography was used to isolate ribosomal subunits or ribosomes from partially purified or complex lysates of mycobacterium and baker's yeast for downstream functional characterizations (*19, 20*). Though somewhat successful, these methods did not find a wider audience or everyday use. Homoamino acid polymers, particularly poly-lysine, have been widely used for various scientific applications. Its interactions and applications with nucleic acids have been documented for DNA

111   extraction (*21*), DNA complex condensation (*22*), RNA purification (*23*), and to improve

112   the delivery of siRNA complexes (*24*). However, poly-lysine has not been explicitly

113   employed for the purification of cytoplasmic ribosomes (translating and non-translating),

114   organelle-specific ribosomes (i.e. mitochondria, apicoplast or chloroplast), ribosomes

115   undergoing biogenesis in the nucleus, and overall ribosome- or translation-associated

116   factors. Moreover, the isolation of RNA using poly-lysine or similar moieties was limited

117   to downstream applications. Such isolations were executed on denaturing RNA and

118   protein molecules with complete disruption of the RNA-protein complexes. In such

119   purifications, functional and structural information on RNA-protein complexes for further

120   research was lost, and purified samples could not be used in both scientific and clinical

121   applications for getting insight into ribosomes or translation machinery.

122   Here, we introduce RNA Affinity Purification by Poly-Lysine (RAPPL), a novel

123   method for isolating a variety of functional RNAs. In this study, we focus on isolating

124   ribosomes and translation-associated factors, with multiple examples where RAPPL

125   was used to obtain structural and functional data on translational machinery. We

126   demonstrate, quantitatively and qualitatively, significant enrichment of ribosomes from

127   various biological samples, including some with limited material. The RAPPL-purified

128   material can be used for multiple downstream applications such as mass spectrometry,

129   imaging of translation drug effects, tandem purification assays, and *in vitro* translation

130   assays. RAPPL can be combined with the previously described methods to enrich

131   specific translation complexes and reduce material loss. Finally, to show the power of

132   RAPPL, we perform a straightforward structural biology application of this new method

133   in purifying ribosomes from the human intercellular pathogen *Cryptosporidium*

134   *neoformans,* a difficult-to-process parasite. These ribosomes were structurally

135   characterized by cryo-EM with a resolution of 2.7Å. Notably, prior to this work, *C.*

136   *neoformans* ribosomes eluded structural studies because of their scarcity in purified

137   samples. While RAPPL does not negate – and is compatible with – methods typically

138   employed for this work, it provides a new means of obtaining RNA species for functional

139   and structural study within the expanding translation field. This study focuses on only a

140   subset of the potential applications of RAPPL, overcoming limitations of previous

141   methods for ribosomes and associated translation machinery isolation. The method

142 described here is affordable, straightforward, cost-efficient, and robust, allowing for the

143 purification of high-quality ribosomes and related factors from different sample sizes and

144 materials, from single-cell organisms and isolated/cultured cells to organs and whole

145 organisms.

146

Results

147

148

Method Overview – RAPPL enriches ribosomes and associated factors

149

150

151 The full details of RAPPL are described in the Methods section. RAPPL is an

152 anion exchange and affinity-based purification method that exploits the negatively

153 charged backbone of RNA and positively charged ε-amino groups of poly-lysine at the

154 physiologically relevant pH 7.5 (Figure 1A). For the purification of ribosomes and

155 associated factors, cells or entire organisms are cultured and processed to specific

156 application requirements. Lysis is performed in a typical ribosome isolation low-salt

157 buffer containing DNase I, RNase inhibitor, and protease inhibitors. Crude lysate is

158 clarified from cell membranes and non-soluble particles by short centrifugation and then

159 bound to magnetic poly-lysine beads for an average of 15-30 minutes at 4□. The beads

160 are then washed in a buffer without detergent. Elution is carried out by incubating the

161 beads in a wash buffer containing poly-D/L-glutamic acid for 15 minutes at either room

162 temperature or 4□. The procedure can be performed on an average time frame of 45-60

163 min, and the eluted material can be stored or applied to downstream applications.

164 Compared with more traditional methods, the workflow is displayed in Figure 1A.

165 To determine the capacity and possibility of poly-lysine beads to bind ribosomes

166 and translation-associated material, we incubated ribosomes from the PURExpress® *in*

167 *vitro* translation system (NEB) with commercially obtained poly-lysine beads

168 (Supplementary Figure 1). We visualized control and ribosome-bound beads via

169 transmission electron microscopy (TEM). The ribosomes were visibly associated with

170 magnetic particles coated with poly-lysine compared to beads without ribosome

171 incubation (Supplementary Figure 1). The beads incubated with ribosomes also appear

172 darker, with increased negative staining, and have less feathering at their periphery,

173 suggesting dense ribosome binding over the surface of the beads. In support of this

174 observation, adding elution buffer with poly-D-glutamic acid to the beads increased the

175 number of ribosomes in imaging fields, arguing for strong surface binding of the

176 ribosomes to the poly-lysine beads.

177 To assess the possible use of poly-lysine beads for the purification of ribosomes

178 from complex lysates, we used lysates obtained from *E. coli* strain DH5α, HEK-293

179 cells, Human Dermal Fibroblasts (HDFs), and HeLa cells (Figure 1B and

180 Supplementary Figure 2). After the RAPPL procedure (Figure 1A), we employed 20% of

181 the total sample to determine the quality of the purified material. A typical yield from 5 to

182 10 million human cultured cells using 100 μL of slurry poly-lysine beads was 80-120ng.

183 We used agarose gel electrophoresis for human cell lines (Figure 1B). All three RAPPL

184 purified samples from human cell lines indicated significant amounts of 28S and 18S

185 rRNAs and tRNAs based on controls, commercial *in vitro* translation lysate from HeLa

186 cells, and purified yeast tRNAs, respectively. *E. coli* DH5α isolated ribosomes were

187 analyzed by bioanalyzer (Supplementary Figure 2). A typical RAPPL total RNA yield

188 from 50 mL *E. coli* cell culture lysate was 100-120ng. The analyzed sample indicated

189 significant enrichment of both 16S and 23S rRNAs and shorter RNA species.

190 To further demonstrate RAPPL enrichment of ribosomes and translation-

191 associated factors, such as ribosomal proteins and initiation factors, over those not

192 associated with protein synthesis, we turned to CRISPR/Cas9-engineered HEK-293 cell

193 lines. RAPPL was performed using lysates from HEK-293 cell lines in which uS13

194 (RPS18) and uL4 (RPL4) have been Flag- and HA-tagged, respectively, by insertion of

195 tag sequences in endogenous loci of the appropriate gene (Supplementary Figure 3).

196 Western blot analyses of RAPPL purified HEK-293 samples indicated complete binding

197 of tagged ribosomal proteins (uS13, uL4) to poly-lysine beads without a visible band in

198 either flow-through or wash fractions (Figure 1C). In addition to the tagged proteins, we

199 have tested the binding of non-tagged 40S subunit ribosomal protein uS9 (RPS16),

200 eIF3a, and eIF4A1 initiation factors, and GAPDH protein. While uS9 and eIF3a were

201 readily detectable in poly-lysine bound fractions, heavily abundant eIF4A1 was

202 detectable in all fractions, whereas GAPDH remained only in the flow-through fraction

203 during the RAPPL procedure (Figure 1C).

204   Finally, to fully detail the repertoire of proteins enriched by RAPPL, the

205   purification procedure was performed on HEK-293 cells and *E. coli* strain DH5α lysates

206   in triplicate, followed by quantitative mass spectrometry analysis (Figure 1D,

207   Supplementary Figure 4, and Supplementary Table 1 and 2). We directly compared

208   ribosomal proteins to all other proteins by abundance in cell lysate (input), flowthrough

209   (FT), and poly-lysine bead-bound (IP). We observed enrichment in ribosomal proteins in

210   poly-lysine bound fractions from *E. coli* and HEK-293 cells (Figures 1D and

211   Supplementary Figure 4).70% and 30% of all poly-lysine bound proteins were ribosomal

212   proteins in the case of *E. coli* and HEK-293 cell pull-downs, respectively. We detected

213   81 annotated human ribosomal proteins in HEK-293 pull-down (Supplementary Table 1)

214   and 52 annotated E. coli ribosomal proteins (Supplementary Table 2). Moreover, after

215   incubation with poly-lysine beads, the flowthrough fraction of HEK-293 cell lysate was

216   almost entirely depleted from ribosomal proteins (Figure 1D). Human ribosomal proteins

217   represented 1% of total proteins in flow-through fraction, compared to approximately

218   13% in starting lysate and 30% of poly-lysine bound fraction (Figure 1D). These results

219   further confirmed ribosome enrichment and efficient binding to poly-lysine beads seen

220   previously in western blot analysis of multiple ribosomal proteins (Figure 1C). In addition

221   to the enrichment of ribosomes, as seen by the analysis of ribosomal proteins, we also

222   noticed enrichment in ribosome- and translation-associated proteins (Supplementary

223   Tables 1 and 2). In the top 100 proteins from *E. coli* bound to poly-lysine beads were

224   translation initiation factor 3 (*infC*), elongation factor Ef-Tu (*tufA, tufB*), rRNA processing

225   and maturation factors (*rbfA, hpf, raiA, rnr, rimM*), along with ribosome and nascent

226   polypeptide chain associated proteins such as trigger factor (*tig*) and chaperons (*groL*)

227   (Supplementary Table 2). In the poly-lysine bound data from HEK-293 cells, we could

228   readily detect enrichment of nascent polypeptide chain associated chaperons (HSP70),

229   translation elongation factors (EEF1 and EEF2), all 13 members of eIF3 translation

230   initiation complex, eIF4A1, eIF5 as well as eIF6, among others (Supplementary Table

231   1). Notably, enrichment of eIF3A and eIF4A1 proteins was also previously detected

232   using western blot analyses of poly-lysine bound fractions (Figure 1C).

233   As such, by exploiting the negatively charged RNA backbone and the positively

234   charged ε-amino groups of poly-lysine, we can isolate ribosomes of high quality with a

235   relatively fast protocol from cell lysate. Using RAPPL, we isolate not only ribosomes but

236   most of the expected translation-associated factors (IF-1, IF-2, IF-3, EF-Tu, EF-Ts, EFG

237   EFP, among others in *E. coli* samples, as well as all 13 members of eIF3 complex,

238   eIF4A, eIF5, eIF6, EEF1, EEF2, among others in HEK293 samples). We also isolate

239   many factors that have been suspected to be associated with ribosome and translation

240   (i.e., YhbY (*25*) and YibL (*26*) in *E. coli*, or LARP1 (*27*) and SERBP1 (*28*) in HEK293

241   cells), as well as multiple new candidates that need further confirmation.

242

243   **<u>RAPPL overcomes material scarcity limitations</u>**

244

245   Sample limitations present a major challenge for many purification processes,

246   including those used for ribosomes and translation-associated material. This is often the

247   case for clinically relevant samples, specific cell types, or organs, and it is often

248   exaggerated in parasitology, with intercellular parasites being present in small numbers

249   and at certain stages of various parasite life cycles. We, therefore, tested the lower

250   limits of RAPPL by performing purifications on decreasing ribosome or cell numbers

251   (Figure 2). We first used ribosomes from the PURExpress® System, which provides

252   purified and highly concentrated *E. coli* ribosomes in a known quantity (13.3 mM). We

253   diluted *E. coli* ribosomes in RAPPL lysis buffer starting at 13.3 µM down to 1.3 nM. The

254   ribosomes were then purified using RAPPL, and the eluates were examined by TEM.

255   We could show ribosome isolation from the lowest concentration at 1.3 nM (Figure 2A).

256   To examine method limitations in the context of cell lysates, components of

257   which could easily affect ribosome binding, we performed RAPPL on HEK-293 cells

258   where uL4 (RPL4) and uS4 (RPS9) have been HA- or Flag-tagged by CRISPR/Cas9

259   engineering, respectively (Supplementary Figure 3). We performed a series of cell

260   dilutions, and the lysates were used further for RAPPL. The eluates of RAPPL isolation

261   were then analyzed by western blot using αHA-HRP or αFLAG antibody to detect the

262   tagged uL4 (Figure 2B) or uS4 (Supplementary Figure 5) proteins, respectively. Results

263   indicated a lower detection limit by western blot at 5,000 or 10,000 cells for uL4 and uS4

264   tagged cell lines, respectively (Figure 2B and Supplementary Figure 5).

265   Mammalian cell lines can be easily cultured in high abundance, with larger cells

266   containing significantly more ribosomes than other clinically significant organisms, such

267   as the malaria-causing parasite - *Plasmodium falciparum*. Growing and maintaining

268   synchrony of the large parasite cultures in replicates necessary for some studies is

269   difficult and costly. Additionally, growing parasites to high parasitemia to reduce flask

270   numbers and materials generates stress conditions that confound results and isolation

271   of ribosomes. We, therefore, wanted to test the cell number limitations of RAPPL to

272   purify from *P. falciparum* NF54 cell line. We engineered this *P. falciparum* cell line with

273   CRISPR/Cas-9 by inserting an HA-tagged mNeonGreen reporter in the C-terminus of

274   ribosomal RACK1 protein (*Pf*RACK1-mNeonGreen-HA, Supplementary Figure 6).

275   Parasites were synchronized at the ring-stage, grown to ~5% parasitemia in 3%

276   hematocrit. Late-stage parasites were isolated via MACS magnet purification (*29*).

277   Parasites were counted using the countess cell counter. Cells were then diluted to

278   5×10^7, 1×10^7, 5×10^6, and 1×10^6 cells, lysed, and the clarified lysate used in the RAPPL

279   method. The products were analyzed by western blotting with αHA-HRP or α-uS11

280   (RPS14) antibody (Figure 2C and Supplementary Figure 7). Our results indicate that we

281   can detect tagged or non-tagged ribosomal proteins isolated from down to one million *P.*

282   *falciparum* cells. Our results indicate that RAPPL can purify ribosomes and translation-

283   associated factors from relatively small quantities of starting material. Current detection

284   levels associated with 1 nM *E. coli* ribosome concentration and western blot analysis of

285   5000 RAPPL purified HEK-293 or 1×10^6 of *P. falciparum* cells.

286

287   **<u>RAPPL is amenable to a wide variety of material and organism types</u>**

288

289   To test whether the RAPPL method may be used as a versatile tool for isolating

290   ribosomes regardless of starting material, we applied RAPPL to a range of sample

291   types, from single-cell organisms and cultured cells to tissues and whole organisms. In

292   each case, we isolated translation-associated materials (i.e., ribosomes) that we then

293   visualized by TEM (Figure 3). RAPPL was efficient in isolating ribosomes regardless of

294   starting material type and quantity. However, slight modifications to the lysis step were

295   necessary but amenable to ensure success for each sample. To ensure the lysis of

296 single-cell organisms (Figure 3A) (i.e., *E. coli*, *S. cerevisiae*, *T. gondii*, *P. falciparum*,

297 and *C. parvum*), cell breaking was done by bead-beating. For samples containing high

298 tissue organization (i.e., perfused mouse organs and *C. elegans*), they were flash

299 frozen, resuspended in buffer, and bead-beating was used to lyse them (Figure 3B).

300 The *D. rerio* was further processed by first finely scoring and segmenting the specimen

301 using a scalpel, followed by flash-freezing in liquid nitrogen and pulverization using a

302 mixer miller (Figure 3B). Lysis of all samples was performed in similar buffers with two

303 exceptions. In the case of *P. falciparum* cells, we used well-documented specific lysis

304 buffer conditions necessary for ribosome isolation and stripping of ribosomes from the

305 endoplasmic reticulum (*30*). This was also applied to *C. parvum* sporozoites.

306 Additionally, high levels of heme present in red blood cells were avoided by using the

307 previously mentioned MACS magnet purification of the parasite (*29*). RAPPL is,

308 therefore, highly adaptable to various starting materials.

309   In contrast to bacterial cells, eukaryotic cells contain organelle-specific

310 ribosomes. Mass-spectrometry analyses indicated that RAPPL enriches both

311 cytoplasmic and mitochondrial ribosomes (Figure 1D, Supplementary Figure 4, and

312 Supplementary Table 1-3). Besides subcellular compartment-localized ribosomes (e.g.,

313 mitochondria and chloroplasts in plants), ribosome biogenesis is compartmentalized in

314 the nucleus. Mass spectrometry analyses of HEK-293 lysate also indicated enrichment

315 of multiple ribosome biogenesis factors using RAPPL (Supplementary Table 2). As

316 such, to further indicate the versatility of our method, we sought to separate

317 compartment-localized ribosomes from cytoplasmic ones (Figure 3C). We isolated the

318 mitochondrial, nuclear, and cytoplasmic cell fractions using the previously published

319 method (31) or commercially available kits (32-34). Separation of cytoplasmic and

320 mitochondrial fractions was done in CRISPR/Cas9 engineered uS4-Flag tag HEK-293

321 cell line while separation of cytoplasmic and nuclear fractions was executed in uL4-HA-

322 tagged HEK-293 cell line. Lysates from cellular compartments and cytoplasm were used

323 as a starting point for RAPPL procedures.

324   The RAPPL eluates were then visualized by TEM (Figure 3C). Images of each

325 fraction contained unique sets of ribosome-like particles indicating the separation of

326 cytoplasmic-, mitochondrial-, and nuclear-associated ribosome particles. We used

327   western blot analyses to validate the separation of cellular compartments and
328   enrichment of ribosomal particles (Supplementary Figure 8). To demonstrate
329   cytoplasmic and mitochondrial fraction separation, we used a Flag antibody for uS4-
330   Flag and mitochondrial ribosomal protein S35 (mRPS35) specific antibody for
331   cytoplasmic and mitochondrial ribosomes, respectively. uS4-Flag protein was strongly
332   enriched in cytoplasmic lysate and RAPPL eluate, while mRPS35 was only detected in
333   mitochondrial lysate and RAPPL eluate (Supplementary Figure 8A). In the case of
334   nuclear and cytoplasmic fractions, we used HA antibody to detect the uL4-HA protein.
335   Analysis revealed the presence and enrichment of large ribosomal subunit uL4 protein
336   in both cytoplasmic and nuclear lysates and RAPPL eluates (Supplementary Figure 8B).
337   The ratio of uL4 in lysate and RAPPL elution followed previously observed enrichment
338   in RAPPL eluates, indicating that most of the uL4 protein is present in the cytoplasmic
339   fraction of HEK-293 cells. A small portion of uL4 ribosomal protein was detected in the
340   nucleus, possibly involved in ribosome biogenesis. Topoisomerase II β-specific antibody
341   was used to confirm the separation of nuclear fraction (Supplementary Figure 8B).
342   Taken together, these results indicate that we can fractionate cell compartments and
343   use RAPPL to isolate cytoplasmic, nuclear, and mitochondrial ribosomal particles to
344   obtain insight into compartment-specific translation machinery in the case of the
345   mitochondria or into ribosomes undergoing biogenesis from the nuclear fractions. These
346   results demonstrate that RAPPL can robustly isolate translation-associated material
347   from a wide range of substances – single cells, tissues, or whole organisms. The
348   method is further adaptable to the ribosome isolation requirements of different
349   organisms or cellular compartments (cytoplasmic, mitochondrial, nuclear, among
350   others), making it a versatile new tool.

351

352   **RAPPL is compatible with current technologies and methodologies for the study**
353   **of protein synthesis**

354

355   To further test the applicability of the RAPPL method, we sought to determine
356   whether the ribosomes and associated translation factors generated by RAPPL can be
357   used to study protein synthesis, the effects of known translation-associated drugs, or

358 the purification of translation-associated complexes. We first used commercial

359 eukaryotic *in vitro* translation kits as proof of concept (Supplementary Figure 9). We

360 directly bound wheat germ and HeLa cell lysates to the RAPPL beads or mixed lysates

361 with eGFP mRNAs, and after protein synthesis was carried on for 2 hours, samples

362 were subjected to RAPPL. The eluates were then visualized by TEM. The micrographs

363 show that the translation architecture is maintained throughout the purification, whereby

364 ribosomes remain bound to mRNA and indicate possible organization in polysomes

365 (Supplementary Figure 9).

366   To determine if RAPPL can be used to assay the effects of different drugs on

367 cultured cells, we performed RAPPL using HEK-293 cells treated and lysed in the

368 presence of various translation inhibitors. Visualization by TEM showed inhibitor-

369 dependent variation in ribosome organization versus untreated controls (Figure 4A).

370 The organization of ribosomes treated with translation elongation inhibitors

371 cycloheximide and anisomycin tend to show more polysomes (i.e., 'beads on a string').

372 In contrast, the translation initiation inhibitor harringtonine reduced this effect by having

373 more monosomes (i.e., individual ribosomes). Control samples (without inhibitors)

374 showed the combination of monosomes, some disomes, and separated subunits (Fig

375 4A). Naturally, cryo-EM at high resolution can confirm the observations mentioned

376 above beyond any doubt. However, the idea behind the presented panels of Figure 4A

377 is to show that the incubation with poly-lysine beads and the subsequent elution do not

378 seem to interfere with the global translation landscape.

379   Polysome profiling is an invaluable tool for studying many aspects of protein

380 synthesis. However, isolating RNA and protein from the generated fractions is

381 cumbersome, with a significant sample loss (*20*). To determine if RAPPL was

382 compatible with these sucrose-containing fractions, we performed polysome profiling

383 using HEK-293 cells. The fractions for the subunits/monosomes, light polysomes, and

384 heavy polysomes were pooled, respectively, and subject to RAPPL. The eluates were

385 then visualized by TEM (Figure 4B). Our results show that RAPPL is compatible with

386 polysome profiling, and ribosome organization is once again maintained (Figure 4B),

387 allowing our method to enrich ribosomes from these fractions while removing the

388 contaminating sucrose for further analysis.

389   Finally, we wanted to know whether RAPPL can be used as a starting point for

390 further purification of certain translation complexes. Tandem affinity purifications often

391 isolate specific translation complexes or improve the final sample purity. Therefore, we

392 performed a tandem RAPPL-αHA-bead purification using *E. coli* cells in which the eGFP

393 construct, N-terminally tagged with a double HA tag followed by an engineered TEV-

394 protease cleavage site, was expressed under an arabinose inducible promoter (Figure

395 4C). In this case, we wanted to isolate translation complexes associated with the

396 nascent polypeptide chain of the eGFP reporter. The expression of eGFP was induced

397 by the addition of arabinose in the media. Non-induced cells served as a control. Cells

398 were lysed in the absence or presence of chloramphenicol (CHL) - a translation

399 elongation inhibitor for *E. coli* ribosomes. The clarified lysates were subjected to RAPPL

400 and eluates from poly-lysine beads were then incubated with αHA magnetic beads. The

401 αHA beads were then washed and eluted with the addition of His-TEV Protease in the

402 wash buffer. The αHA-bead eluates were then analyzed by TEM (Figure 4C). Images of

403 control non-induced samples did not contain any ribosomes, while induced samples

404 indicated the presence of ribosomes or even polysomes. The observed difference in the

405 number of ribosomes and observed polysomes in induced samples was attributed to

406 CHL. Addition of CHL during lysis prevents run-off of elongating ribosomes and release

407 of the nascent polypeptide chain, resulting in a higher number of ribosomes associated

408 with HA-beads and in RAPPL eluate from CHL-treated lysates (Figure 4C).

409   Therefore, RAPPL can be used with current technologies and methods to study

410 protein synthesis. RAPPL allows for sample enrichment from and removal of sucrose,

411 which is often incompatible with downstream techniques. Ribosome binding and

412 organization is maintained throughout the purification process, suggesting efficacy in

413 structural applications and the possibility to use RAPPL as an enrichment step for

414 tandem purification of specific translation complexes with tagged target proteins. Finally,

415 translation inhibitors may be used to perturb ribosomes and translation factor

416 equilibrium in such studies to obtain the desired fractions and purity of complexes of

417 interest.

418

RAPPL eluates are compatible with functional and downstream clinical applications

While the products of RAPPL appear to have the visual hallmarks of functional translation, we wanted to determine if RAPPL-isolated ribosomes maintain their functionality – essentially, could RAPPL-isolated ribosomes translate reporter mRNA into protein. To test the activity of isolated ribosomes, we used *E. coli* cells and a widely used PURExpress® *in vitro* translation system kit (*31*). We first tested whether adding poly-D-glutamate, used for ribosome elution in the RAPPL method, would affect PURExpress® *in vitro* translation of an eGFP reporter. We did not observe any difference in the yield of eGFP protein synthesized by the PURExpress® kit with or without adding poly-D-glutamate (Supplementary Figure 10A). We next substituted the kit-supplied ribosomes with an increasing amount of RAPPL eluate from *E. coli* DH5α cells mixed with a DNA template encoding the eGFP reporter gene (Figure 5A). The estimated concentration of RAPPL-isolated ribosomes used in *in vitro* translation was 20-100 times lower than those used in the PURExpress® kit (approximately 2.4 µM). The reaction products were analyzed using a western blot to detect eGFP protein (Figure 5A). Results demonstrated the synthesis of eGFP reporter that is dependent upon the addition of increasing amounts of RAPPL-isolated ribosomes, and as such indicated that performing RAPPL on *E. coli* DH5α cell lysates resulted in enrichment of functional ribosomes, which can be used for *in vitro* translation systems. The control reaction (without a DNA template) displayed no eGFP synthesis (Figure 5A). We were also able to follow eGFP reporter protein synthesis from RAPPL-isolated ribosomes by following the fluorescence of newly synthesized reporter protein using a plate reader (Figure 5B). This further corroborates the robustness and functionality of RAPPL-isolated ribosomes and creates a simple assay to follow the functionality of RAPPL-isolated ribosomes. In addition to RAPPL purified and eluted ribosomes used in the solution mentioned above assays (Figure 5A and 5B), incubation of RAPPL beads used to isolate *E. coli* DH5α ribosomes with the PURExpress® buffer and DNA template resulted in active translation and synthesis of eGFP protein analyzed by western blot analyses (Supplementary Figure 10B). As such, RAPPL ribosome eluates or on-bead

450   isolated ribosomes could perform *in vitro* translation reactions and translate reporter

451   genes into protein, drastically shortening *in vitro* translation assays (Figure 5A,5B and

452   Supplementary Figure 10B).

453   To further test whether fast isolation of ribosomes by RAPPL could be used in

454   clinical applications, we applied our method to test antibiotic-resistant *E. coli* strains

455   associated with urinary tract infections. We used previously described patient clinical

456   isolates of uropathogenic *E. coli* (UPEC) - Ec13 and Ec24 (*32*). These *E. coli* strains are

457   trimethoprim-sulfamethoxazole and ciprofloxacin-resistant and have a broad-spectrum

458   secondary multidrug transporter (MdfA+), providing additional antibiotic resistance (*33*).

459   The Ec24 strain has been confirmed to contain active rRNA methylase (ermB), which

460   results in the methylation of 23S rRNA (A2058), reducing erythromycin (ERY) binding to

461   ribosomes (*34*). Additional E. *coli* strains with plasmid-encoded rRNAs and engineered

462   rRNA mutations were also used as controls (*35*). The SQ110 ΔTC 16S – A1408G strain

463   carries a mutation that provides resistance to spectinomycin, kanamycin (KAN), and

464   gentamicin, while the SQ110 ΔTC 23S – A2058G provides resistance to spectinomycin

465   and ERY. The SQ110 plasmid carries a selection cassette that encodes aminoglycoside

466   3'-phosphotransferase II enzyme (*35*) that inactivates KAN by phosphorylation in cells.

467   However, ribosomes isolated from ΔTC 23S – A2058G strain should not have

468   resistance to KAN. Although both strains are kanamycin resistant and can grow on

469   KAN-containing bacterial agar plates, only a small subunit rRNA mutation (A1408G)

470   provides ribosome resistance to KAN (*35*). The SQ110 ΔTC 23S – A2058G plasmid

471   contains a mutation in the large subunit rRNA (A2058G) that provides resistance to

472   ERY and CLI (*35*). Using *E. coli* lab strain DH5α as a control, we tested antibiotic

473   resistance for each *E. coli* strain by growing them on bacterial agar plates without (LB

474   only) and supplemented with antibiotics (ERY, KAN, chloramphenicol (CHL), and

475   clindamycin (CLI); (Figure 5C). All *E. coli* strains were able to grow on a plate without

476   antibiotics (LB only). SQ110 strains grew slower than other *E. coli* strains due to the fact

477   that all ribosomes in these strains are encoded by a single copy of rDNA located on a

478   plasmid. Based on agar plate growth, the Ec13 UPEC strain was not resistant to CHL

479   but to KAN, CLI, and partially to ERY (Figure 5C). The Ec24 UPEC strain was resistant

480   to ERY, CLI, and CHL, while no resistance to KAN was observed (Figure 5C). As

481 expected, SQ110 strains were resistant to KAN due to the plasmid antibiotic selection
482 cassette and A1408G mutation in the 16S rRNA of SQ110 ΔTC 16S – A1408G strain
483 (*35*)(Figure 5C). SQ110 ΔTC 16S – A1408G did not show resistance to any other
484 antibiotics. Besides plasmid-encoded KAN resistance, SQ110 ΔTC 23S – A2058G also
485 indicated no resistance to CHL and strong resistance to ERY and CLI, due to
486 engineered A2058G mutation in 23S rRNA (Figure 5C). *E. coli* DH5α showed partial
487 antibiotic resistance to ERY and CLI and no resistance towards KAN or CHL (Figure
488 5C). The partial resistance of *E. coli* DH5α on ERY and CLI plates is due to 100 mg/mL
489 of ERY and CLI used for agar plates.

490 To test whether observed antibiotic resistance is due to the specific methylation
491 or mutation of ribosome nucleotides versus multidrug transporters, we used the RAPPL
492 method on cell lysates from small bacterial cultures (volume of 50 mL). Each *E. coli*
493 strain was grown to an exponential phase, cells were harvested, and RAPPL was
494 performed. The RAPPL eluates from each strain were then used in the PURExpress® *in*
495 *vitro* translation system to synthesize the eGFP reporter, as shown above (Figure 5A).
496 All RAPPL purified ribosomes were tested for functionality in the control conditions (con,
497 no antibiotic added in *in vitro* translation reaction; Figure 5D). After successful testing
498 and indication of robust synthesis of eGFP reporter by western blot analyses, we carried
499 on by testing the same set of RAPPL-isolated ribosomes but with the addition of
500 antibiotics, previously used for testing of growth on agar plates (Figure 5C). We used
501 antibiotic concentrations based on previous studies with bacterial resistance strains and
502 engineered ribosome mutations (*35-38*). Only Ec24 and SQ110 ΔTC 23S – A2058G
503 RAPPL-isolated ribosomes were able to *in vitro* synthesize eGFP protein in the
504 presence of 5 µM ERY or 50 µM CLI (Figure 5D), thus confirming the presence of the
505 ermB methylase in the Ec24 strain and engineered A2058G mutation in the ΔTC 23S –
506 A2058G strain, respectively. In addition to ERY and CLI resistance, Ec24 RAPPL-
507 isolated ribosomes indicated functional resistance in the presence of 50 µM CHL in an
508 *in vitro* translation reaction (Figure 5D), confirming previous growth of this *E. coli* strain
509 on agarose plates supplemented with CHL (Figure 5C). We did not observe any other
510 RAPPL-isolated ribosomes with CHL resistance. Ribosomes isolated from SQ110 ΔTC
511 23S – A2058G, as well as Ec24 ribosomes, could not synthesize eGFP in *in vitro*

512   translation reactions in the presence of 1.5 or 2 µM KAN. The Ec24 strain did not show

513   resistance on agarose plates supplemented with KAN.

514   In contrast, SQ110 ΔTC 23S – A2058G strain kanamycin resistance was

515   provided by SQ110 plasmid, which carries a selection cassette that encodes

516   aminoglycoside 3'-phosphotransferase II enzyme (35) that inactivates KAN by

517   phosphorylation in cells. RAPPL-isolated ribosomes from SQ110 ΔTC 16S – A1408G

518   strain were the only ribosomes capable of synthesizing eGFP reporter in the presence

519   of 1.5 or 2 µM KAN (Figure 5D). The ΔTC 16S – A1408G ribosomes could synthesize

520   eGFP reporter only in the control conditions (no antibiotic present) or in the presence of

521   KAN, confirming the A1408G 16S rRNA mutation responsible for KAN resistance.

522   Interestingly, Ec13 RAPPL-isolated ribosomes did not show any antibiotic resistance in

523   *in vitro* translation assays (Figure 5D). This contrasts sharply with resistance assessed

524   by agarose plates supplemented with antibiotics, where Ec13 cells demonstrated strong

525   resistance to KAN and CLI, and partial resistance to ERY (Figure 5C). We conclude that

526   Ec13 can grow on bacterial agar plates supplemented with KAN, CLI, and ERY,

527   ostensibly due to its secondary multidrug transporter, not ribosome-associated

528   resistance mechanisms (Figure 5C and 5D).

529   Our results indicate that *E. coli* RAPPL-isolated ribosomes are translationally

530   competent and allow the flexibility of on- or off-bead reaction setup. Therefore, RAPPL

531   can be used to rapidly screen for ribosome or translation factor-associated resistance

532   mechanisms, with plate-based assays confirming alternative mechanisms. Bacterial

533   strains – lab, clinical, or otherwise – that can be cultured or isolated even in relatively

534   small quantities are accessible for study. These data show the ability of RAPPL to

535   isolate and study translation-associated antibiotic mechanisms of resistance from a

536   clinical setting.

537

538

539   **RAPPL generates high-quality materials for structural determination**

540

541   Finally, we sought to determine the compatibility of RAPPL with structural

542   applications and whether the ribosomes-isolated would be of sufficient quality for

543 structural determination using cryo-electron microscopy. We applied RAPPL to
544 *Cryptococcus neoformans* cells grown in exponential phase isolated in the presence of
545 cycloheximide. *C. neoformans* was selected for two reasons: 1) an 80S structure had
546 yet to be determined, and 2) to determine if the anionic polysaccharides heavily present
547 in the cell wall that are released into the lysate during bead-beading would interfere with
548 RAPPL purification. A small portion of RAPPL eluate was first examined by TEM to see
549 the uniformity of the collected and purified sample (Figure 6A). Since, isolated *C.*
550 *neoformans* ribosomes represented a majority of the particles in TEM images and had
551 an adequate concentration, the RAPPL eluate was applied to carbon-coated cryo-EM
552 grids, and 2,498 images were collected (Supplementary Figure 10). From an initial
553 646,683 particles, 399,114 particles were used for 2D classification into 50 classes, and
554 294,300 particles were refined to ultimately generate a 2.7 Å map with the material
555 eluted from RAPPL straightforwardly (Figure 6 and Supplementary Figure 11).

556 This Cryo-EM structure represents the first 80S ribosome structure of *C. neoformans*,
557 an encapsulated yeast causing cryptococcosis and potential death to immuno-
558 compromised and immunosuppressed individuals through infection of the lungs and
559 brain. Moreover, this 2.7 Å structure of 80S ribosomes isolated from 1×10^8 *C.*
560 *neoformans* cells fundamentally indicates that the RAPPL method can be used to
561 rapidly isolate ribosomes from biological material, cost-friendly, and efficiently for high-
562 resolution structural studies.

563
564

565 **Discussion**

566 The isolation of ribosomes from different cell types, organs, and organisms
567 imposes several challenges, primarily due to the unique biochemical environment and
568 cellular compositions. The most common problem associated with ribosome isolation is
569 contaminant presence, which can affect RNA quality and protein content during
570 isolation. Different cell/tissue types require different adjustments based on the cell type.
571 Further, the cellular structure of the tissue can affect ribosome isolation; tissues with
572 dense cellular arrangements, such as brain or heart tissue, can be more challenging to
573 homogenize, leading to inefficient lysis and ribosome extraction. Lastly, different cell

574 types/tissues require specific pH levels and ionic conditions for optimal ribosome

575 extraction. Maintaining such conditions during isolation is critical, as deviations can

576 reduce ribosomal activity and purity. Traditional procedures are time-consuming,

577 complex, and often not suitable for all tissue types, especially when rapid isolation is

578 needed for downstream application. Maintaining RNA integrity or achieving high yield

579 and purity simultaneously can be challenging. Methods that obtain purity may reduce

580 yield, making it difficult to obtain ribosomes that are both functional and free of

581 contaminants. Notably, the activity of isolated ribosomes can vary depending on the

582 tissue and isolation method used. In summary, the isolation of ribosomes from different

583 cells/tissues is fraught with challenges that stem from tissue-specific characteristics.

584 We developed a rapid, facile, and parsimonious method to purify ribosomes and

585 associated factors to overcome these challenges. RAPPL is a robust and versatile

586 method capable of enriching ribosome-associated materials from a wide range of

587 sample types, even those in low abundance and cellular compartments. The

588 downstream application of isolated ribosomes can go in many directions, such as

589 translational studies, drug development, functional analysis, ribosome profiling,

590 structural biology, and posttranslational modification studies. We were able to

591 demonstrate the compatibility of RAPPL with several of these. Our method is well-suited

592 to the currently available technologies and methodologies (Figure 4A & 4B). RAPPL can

593 also be used to study the effects of translational inhibitors on eukaryotic ribosomes

594 (Figure 4B), which could be coupled with factor-specific tandem purifications for further

595 analysis (Figure 4C). Using various *E. coli* strains, including patient-isolated UPEC

596 strains, we can isolate ribosomes via RAPPL and subsequently determine translation-

597 associated mechanisms of antibiotic resistance (Figure 5C and 5D).

598 The ability to isolate translational machinery from limited starting materials would

599 prove advantageous for those fields in which this is a major limiting factor (e.g., patient

600 samples, clinical isolates, and several parasites). Here, we demonstrate the ability of

601 RAPPL to isolate ribosomes from as little as 5,000 - 10,000 mammalian cells (Figure 2B

602 and Supplementary Figure 5). However, mammalian cells harbor significantly more

603 ribosomes than other organisms. We further demonstrate that our method can isolate

604 and detect ribosomes from as low as one million *P. falciparum* NF54 cells (Figure 2C

605 and Supplementary Figure 7). This is significantly less than necessary for other

606 methods used to study ribosomes and protein synthesis. Often, ~10^8 *P. falciparum* cells

607 or more are used in other methodologies like polysome profiling, which depends on

608 gradient volume, with larger gradient sizes requiring up to five times more material. This

609 limitation prevents the use of many clinically relevant organisms and patient biopsies in

610 such studies. While RAPPL will not replace current methods used to study ribosomes

611 and translation, the lower cellular threshold enables researchers to gain access to this

612 data for those organisms and clinical samples that cannot be isolated in sufficient

613 quantities for said traditional methods.

614 RAPPL purified ribosomes from a wide range of organisms with minor

615 modifications to cell lysis when necessary. This method worked with single celled

616 organisms – intracellular and extracellular – and cultured cells, as well as tissues and

617 whole organisms (Figure 3). Processing single-celled organisms and cultured cells is

618 done similarly. Lysis of these organisms is done using detergent (triton-X100). For those

619 that have cell walls (bacteria, yeast) or multiple membranes (*P. falciparum*), bead-

620 beating is introduced to ensure membrane rupture. In the case of the intracellular

621 parasite *T. gondii*, the host cells are lysed by shearing prior to parasite lysis. *P.*

622 *falciparum* requires lysis in potassium acetate to ensure ribosome release from the

623 endoplasmic reticulum (*30, 39*), which must then be diluted (1:8) to enable ribosome

624 binding to the beads. This dilution did not prevent enrichment by RAPPL (Figure 3A).

625 However, these lysis methods are known and currently used in their respective fields.

626 Tissues, such as the perfused mouse organs used here, and whole organisms require a

627 breakdown of the tissue structure and cell wall by flash-freezing and subsequent bead-

628 beading or milling to ensure the release of the cytoplasmic contents (Figure 3B). Whole

629 organisms with complex tissue organization, like the *D. rerio* used here, require sample

630 scoring prior to flash-freezing and milling (Figure 3B). Again, these methods are already

631 employed, demonstrating RAPPL's adaptability for a multitude of sample specimen

632 types (Figure 3). Of import are the conditions under which RAPPL lysis and binding are

633 performed regarding those necessary to maintain ribosome subunit association with

634   mRNA, should this be desired, as well as those needed for other translation-associated
635   factors.

636   The study of mitochondrial ribosome dysfunction is of clinical importance with a
637   host of life-threatening outcomes (*40*). Using RAPPL, we were able to purify
638   mitochondrial ribosomes rapidly (Figure 3C and Supplementary Figure 8). Our method
639   could be combined with current laboratory or clinical studies to examine mitochondrial
640   ribosomes for functional, composition, and structural analysis (*15, 16*). Although we
641   prioritized using RAPPL for the study of protein synthesis, the method can purify other
642   pertinent ribosome-associated activities, such as ribosome biogenesis (Figure 3C and
643   Supplementary Figure 8). Ribosome biogenesis is essential to the cell cycle
644   (proliferation, differentiation, apoptosis, et cetera), cell and organismal development and
645   plays roles in malignant cell transformation and therapeutic resistance (*41-43*). The
646   study of ribosome biogenesis also provides insights into microbial diversity through
647   ribosome evolution, function, and the development of therapeutic resistance (*9, 44*). The
648   ability to quickly and efficiently harvest this material enables study in these areas, which
649   we were able to demonstrate (Figure 3C and Supplementary Figure 8). Thus, RAPPL
650   enables the purification and study of ribosomes from various cellular compartments, not
651   only cytosolic ribosomes.

652   Functional and structural analysis of purified ribosomes can provide insight
653   ranging from the effects of drug treatments on the ribosome translation cycles to the
654   outcomes of different cell stressors. Using *in vitro* protein synthesis kits, we were able to
655   visually demonstrate that ribosome organization is maintained by RAPPL
656   (Supplementary Figure 9). We were also able to show that the effects of translation
657   inhibitors on this organization can be visualized using our method (Figure 4A),
658   suggesting that further study of such drug treatments or other stress factors is possible.
659   However, it should be noted, as previously mentioned, that adaptations may be
660   necessary for more nuanced investigation, such as any specific conditions to ensure
661   accessory protein binding and high concentrations of anionic compounds that disrupt
662   poly-lysine: RNA interactions will reduce, if not inhibit, purification by RAPPL.

The compatibility of RAPPL with current technologies like *in vitro* kits and methodologies like polysome gradient profiling provides further flexibility. Enriching from polysome profiling fractions via magnetic bead isolation (Figure 4B) without the necessity of genetic manipulation to introduce affinity tags enables researchers to quickly and freely pursue various avenues of study. It also reduces the time to use isolated products, thereby reducing degradation or complex dissociation that may occur during long centrifugations. Product enrichment using RAPPL over loss often seen with sucrose cushion or gradient centrifugation (*20*) is also a benefit, requiring less starting sample, and RAPPL elution can be used for further purification in tandem with affinity tags associated with the nascent polypeptide chain (Figure 4C), or ribosome or translation associated factors. Purifying and enriching ribosomes is useful for their study in various conditions. However, enriching functioning ribosomes can provide significantly more information through *in vitro* translation studies. Our results indicate that RAPPL products are functional and can be used on (Figure 5A) or off bead (Supplementary Figure 10B), as well as following fluorescence of reporter genes in plate reader assays (Figure 5B) during *in vitro* protein synthesis. This method drastically shortens the time necessary for isolation and functional testing of the isolated ribosomes from bacterial cells, providing a good basis for developing *in vitro* translation kits or lysates from other cells and organisms.

We also demonstrated the clinical applications of RAPPL to study ribosome-associated resistance mechanisms by using clinical UPEC isolates, with mutagenized and lab strains as controls (Figure 5C and 5D). These methods can then be further adapted to plate-based assays (as indicated by Figure 5B)), which lends to the possibility of high throughput assays using ribosomes isolated from various pathogenic organisms on compound libraries. Furthermore, with the right supplementation (i.e., S100 fraction), *in vitro* protein synthesis studies may be possible with eukaryotic organisms.

The purification of ribosomes and ribosomal complexes for structural determination can be quite time and labor-intensive. Here, we demonstrate the ability to obtain cryoEM-ready samples using RAPPL in approximately one hour, producing high-

693 quality structure maps (Figure 6 and Supplementary Figure 11). This process typically

694 requires a significant number of cells, which are sometimes hard to obtain, as is the

695 case with many clinically relevant organisms like the parasites *P. falciparum* or *C.*

696 *parvum*. To isolate certain ribosomal complexes, such as the pre-initiation complex,

697 more material will be needed, followed by polysome profiling and isolation from the

698 desired sucrose fraction(s) by lengthy ultracentrifugation. Throughout this process,

699 sample loss to handling, degradation, and complex dissociation inevitably occurs.

700 RAPPL provides a means of rapid sample enrichment, which can be performed instead

701 of, prior to, or following polysome profiling, depending on what ribosomal complexes are

702 sought. These options can decrease the required starting sample and/or sample loss at

703 key bottlenecks while reducing the time from lysis to grid preparation and, ultimately,

704 structural determination.

705   To summarize, the development of methods like polysome profiling has been

706 instrumental in furthering our understanding of ribosomes, protein synthesis, and gene

707 regulation. However, this method has some limitations, such as meeting cell material

708 requirements, lengthy centrifugation times, costly equipment, and sucrose

709 contamination in fractionated samples. To reduce and circumvent these limitations, we

710 present RAPPL, a method defined by its ease of use, wide range of applications, and

711 adaptability. Using RAPPL, we are able to isolate ribosomes as well as ribosome- and

712 translation-associated factors from a wide variety of specimens and in limited ribosome

713 or cell numbers. As shown by mass spectrometry, RAPPL significantly enriches

714 ribosome- and translation-associated factors. Ribosome organization is also maintained

715 during purification and can be visualized by TEM, demonstrating the effects of the

716 addition of mRNA on in vitro protein synthesis kits or mRNA translation inhibitors on

717 mammalian cell lysates. Ribosomes isolated by RAPPL can be used in functional

718 studies, as we did here, showing ribosome-associated resistance mechanisms using *in*

719 *vitro* protein synthesis kits. This suggests the ability of RAPPL to generate ribosomes

720 for *in vitro* protein synthesis from virtually any organism, given that the right additional

721 factors are supplied, such as those in the S100 fraction. RAPPL is compatible with

722 current methods, enabling ribosome and ribosome-bound protein enrichment from

723 polysome profiling fractions while removing sucrose. RAPPL eluates are also of

724   sufficient quality for structural studies and are capable of producing high-resolution

725   maps by cryoEM for structural determination of ribosomes and ribosome-associated

726   complexes. We hope RAPPL provides researchers with a new means or further

727   flexibility in their ribosome and protein synthesis studies.

728

729

Methods

Cell Culture and Animal Husbandry

Escherichia coli

E. coli DH5α cells, uropathogenic patient isolate *E. coli* strains Ec13 and Ec24 (A kind gift from Dr. Jeffrey Henderson (*32*) and *E. coli* rRNA mutagenized lines SQ110 ΔTC 16S – A1408G and SQ110 ΔTC 23S – A2058G (*35*)(a kind gift from Dr. Nora Vazquez-Laslop and Dr. Alexander Mankin) were cultured overnight in Luria-Bertani (LB) medium. From this overnight culture, 2 mL was used to inoculate 50 mL of LB medium. For mass spectrometry, *E. coli DH5α* cells were grown for 1.5-2 hours. Otherwise, all cells were incubated for 3 hours at 37℃ while shaking at 200 rpm. In the case of rRNA mutagenized lines, cell culture was doubled to 100 mL of LB medium (4 mL inoculation) as these *E. coli* strains grew at approximately half the rate of the other lines.

E. coli serial dilution tests were performed on LB agar plates (TEKNOVA LB broth and agar) with varying concentrations of antibiotics until the most effective concentrations of each antibiotic were found—100 mg/mL of erythromycin (Sigma Aldrich) and clindamycin (Sigma Aldrich), 12.5 mg/mL of kanamycin (Gold Biotechnology) and chloramphenicol (Gold Biotechnology). Cultures for each *E. coli* sample were grown overnight without antibiotics in the LB media, and serial dilution tests were performed the next day. Before serial dilutions, overnight cultures' optical density was equalized to 2.0 within 0.1 at 600 nm (OD_{600}) using a Thermo Fisher NanoDrop. After equalizing overnight cultures, serial dilutions of 10x, 100x, 1000x, and 10000x were dropped on plates in 7 µL increments. Plates were then placed in an incubator at 37°C overnight and imaged the following day using a BIO-RAD ChemiDoc imaging system.

HEK-293, Human Dermal Fibroblasts, and HeLa Cells

HEK T-RExTM-293 cells (R71007, Thermo Fisher), human dermal fibroblasts (HDF, ATCC, PSC-201-012) and HeLa cells (ATCC, CRM-CCL-2) were maintained in DMEM (Gibco) supplemented with 10% heat-inactivated FBS (Gibco), 1×Penicillin Streptomycin and Glutamine (Gibco) and 1 × MEM Non- Essential Amino Acids (Gibco).

759 Cells were grown to 90% confluency and divided 1 to 4 for HEK-293 and HeLa, or 1 to 3
760 for HDFs for continued growth. CRISPR/Cas9 engineered HEK-293 cell lines (uS-4-
761 Flag, uS-13-Flag, and uL-4-HA tagged HEK-293 cells, Genscript) were treated as HEK
762 T-RExTM-293 cells. Cells were incubated with translation inhibitors 20 minutes before
763 collection when indicated. Cells were collected by trypsinization and washed in 1xDPBS
764 (Thermo Fisher # 14190144; with additional inhibitors when noted) by centrifugation at
765 500xG for 5 minutes prior to lysis.

766

Plasmodium falciparum

768 Parasites were cultured as previously described (*45*). Briefly, *P. falciparum* Dd2 or
769 NF54, as well as engineered *Pf*RACK1-mNeonGreen-HA, were maintained by
770 continuous culture at 2-5% hematocrit in human erythrocytes with malaria culture
771 medium (RPMI 1640 supplemented with 5 g/L Albumax II (Gibco), 0.12 mM
772 hypoxanthine (1.2 ml 0.1 M hypoxanthine in 1 M NaOH), and 10 µg/ml gentamicin).
773 Cultures were grown statically under hypoxic conditions in a candle jar atmosphere.
774 Synchronization was done using 5% sorbitol treatment and magnetic purification using
775 MACS cell separation magnets over LD columns. The parasites were washed with 1X
776 PBS prior to lysis.

777

Plasmids and genetic modification of *P. falciparum*

779 The yPM2GT donor vector and Cas9+sgRNA expression plasmid (pAIO3) used to edit
780 *P. falciparum* RACK1 locus has been described previously (*46-48*). For *in-situ* C-
781 terminal tagging of *PfRACK1* with mNeonGreen-3xHA tag, 712 bp immediately
782 upstream of the stop codon (left homologous region [LHR]) and 798 bp of the 3' UTR
783 (right homologous region [RHR]) was amplified from NF54[attB] genomic DNA using
784 primers pairs p1-p3 and p4-p5 respectively. The LHR and RHR amplicons were
785 sequentially cloned into the yPM2GT donor vector between AflII/NheI and XhoI/AflII
786 sites, resulting in the plasmid sPL6. Two guide RNA target sites were selected, and the
787 complementary sense and antisense oligos for each sgRNA were annealed and ligated

788 into the AflII site of the pAIO3 plasmid using an In-Fusion cloning kit (Takara). Before

789 transfection, the donor plasmid sPL6 was linearized using AflII and co-transfected into

790 *P. falciparum* NF54[attB] cells with the Cas9+sgRNA plasmids designed to target

791 *PfRACK1*. Transgenic cells were selected with 2 µM DSM1, and the expected

792 integration was confirmed by diagnostic PCR using p10-p11, p12-p13, and p10-p13

793 primer pairs.

794

Toxoplasma gondii

796 *T. gondii* ME49 parasites were continuously cultured in human foreskin fibroblast (HFF)

797 cell monolayers as previously described (*49*). HFF cells were maintained in Dulbecco's

798 modified Eagle's medium (Invitrogen) supplemented with 10% HyClone fetal bovine

799 serum (GE Healthcare Life Sciences), 10 µg/mL gentamicin (Thermo Fisher Scientific)

800 and 10 mM glutamine (ThermoFisher Scientific) (D10). *T. gondii* parasites were isolated

801 from host cells as previously (*50*). Briefly, parasites were cultured to high parasitemia

802 (~75%) in two T25 flasks. The monolayers were scraped and combined in 10 mL of D10

803 medium. The cell suspension was passed through 22G blunt-end syringe 3 times to

804 disrupt host cells. Host cell debris was filtered out by passing through a pre-wet 3 µm

805 polycarbonate membrane, which was then washed with and additional 5 mL of D10

806 medium. The freed T. gondii cells were pelleted by centrifugation (400 x g for 10 mins).

807 The parasites were washed with 1X PBS prior to lysis.

808

Cryptosporidium parvum

810 Purified *C. parvum* oocysts were graciously provided by the Sibley Lab per the lab

811 protocol (*51*). Oocysts (10^7) were bleached by treating them with 40% bleach and

812 incubating them on ice for 10 mins. The oocysts were removed by centrifugation (900 x

813 g for 3 mins at 4□). The supernatant was removed, and the oocysts were washed three

814 times with 1X DPBS + 1% BSA. Excystation was performed by combining equal

815 volumes of resuspended oocysts (100 µL) and 1X DPBS + 1.5% sodium taurocholate.

816 The oocysts were then incubated for 60-75 minutes at 37℃. Excystation was confirmed

817 by brightfield microscopy (~80%). The parasites were centrifuged for 3 mins at 1400 x g

818 and washed with 1X DPBS twice prior to lysis.

819

Saccharomyces cerevisiae

821 An overnight culture of S. cerevisiae was grown by inoculating 10 mL of yeast-peptone-

822 dextrose (YPD) growth medium with 200 µL of glycerol stock at 30□. The culture was

823 harvested by centrifugation at 3500 x g for 5 mins at 4□. The culture was washed with

824 1X PBS prior to lysis.

825

Cryptococcus neoformans

827 *C. neoformans KN99α* were grown and generously provided by Dr. Tamara Doering's

828 lab (Washington University in St. Louis). Briefly, cultures were grown on yeast extract-

829 peptone-dextrose (YPD) plates for two days at 30□. YPD liquid medium was inoculated

830 with single colonies and grown overnight at 30□ while shaking at 230 RPM. Overnight

831 cultures were diluted to an OD600 of 0.2 and grown to 0.6 (exponential phase). Cultures

832 were pelleted and washed with 1X PBS prior to lysis.

833

Caenorhabditis elegans

835 *C. elegans* worms were generously provided by Dr. Tim Schedl's lab (Washington

836 University School of Medicine). A synchronized population of 2000 - 3000 *C. elegans*

837 embryos were obtained following a two-hour egg lay on NGM plates seeded with *E. coli*.

838 Worms were grown continuously to the young adult stage and harvested before

839 fertilized eggs appeared. Worms were washed 4-times in M9 buffer and then 2-times in

840 deionized, distilled water, pelleted and frozen in liquid nitrogen prior to lysis.

841

Danio rerio

843 Zebrafish (D. rerio wild-type AB) were graciously provided by the Stratman lab, and
844 experimental procedures were done per approved guidelines by the Washington
845 University in St. Louis School of Medicine Institutional Animal Care and Use Committee
846 (IACUC). Fish were euthanized by an ice water bath (5 parts ice/1 part water, 0-4□)
847 separated from ice chips by a fine mesh strainer for a minimum of 10 minutes after
848 cessation of opercular movement. Animals were snap-frozen in liquid nitrogen and
849 stored at -80°C until further use.

850

Mus musculus

852 Perfused mouse organ sections from WT C57Bl6/N mouse (Charles River, Cat#:
853 C57BL/6NCrl were generously provided by the Dr. Maxim Artyomov lab (Washington
854 University School of Medicine) and experimental procedures done per approved
855 guidelines by the Washington University in St. Louis School of Medicine Institutional
856 Animal Care and Use Committee (IACUC). Mice were humanely euthanized in a CO_2
857 chamber. Individual organs (liver and spleen) were removed and snap-frozen in liquid
858 nitrogen. Frozen tissue has been stored at -80°C until further use.

859

RNA Poly-lysine Affinity Purification (RAPPL)

861 Cells, organs, and organisms were maintained as mentioned above. Cells were
862 centrifuged, their growth mediums removed, washed with PBS, and transferred to 2.0
863 mL microcentrifuge tubes. Cells were then resuspended in RAPPL lysis buffer (100 mM
864 HEPES·KOH solution, pH 7.5, 50 mM KCl, 10 mM $Mg(OAc)_2$, 1% Triton-X, 1 mM DTT,
865 Protease Inhibitors (Cell Signaling), 40 U/mL RNaseOUT, 20 U/mL $^{Superas·IN™}$ RNase
866 Inhibitor, 4 U/mL DNase I). Bacterial and fungal samples were resuspended in a ratio of
867 1:2:1 cell pellet: lysis buffer:acid-washed glass beads (Sigma #G8772). Mammalian cell
868 lines and *T. gondii* were resuspended in 500 µL to 1ml of lysis buffer. *P. falciparum* and
869 *C. parvum* were resuspended in 400 µL and 250 µL modified lysis buffer (25 mM K-
870 HEPES, pH 7.5, 400 mM KOAc, 15 mM $Mg(OAc)_2$, 2% Triton-X100, 1 mM DTT,
871 Protease Inhibitors (Cell Signaling), 40 U/mL RNaseOUT, 20 U/mL Superas·IN™

872   RNase Inhibitor, 4 U/mL DNase I). Following lysis, samples in modified lysis buffer were

873   diluted 8X in RAPPL binding buffer (100 mM HEPES-KOH pH 7.5, 10 mM Mg(OAc)$_2$, 1

874   mM DTT, Protease Inhibitors (Cell Signaling), 40 U/mL RNaseOUT, 20 U/mL

875   Superas·IN™ RNase Inhibitor, 4 U/mL DNase I). Perfused organ sections were

876   homogenized and resuspended in 1 mL RAPPL lysis buffer, sonicated two times for 15s

877   at 60 Hz before further bead-beating. For all single-celled organisms, *C. elegans*, and

878   perfused mouse organ sections, bead-beating was performed using a BeadBug™ 3

879   Microtube homogenizer (Benchmark Scientific) for 30s at 4,000 Hz, three times at 4□.

880   For mammalian cell lines, no bead-beating was performed. Following euthanasia, the *D.*

881   *rerio* sample was finely scored and segmented using a scalpel and then flashed frozen

882   by plunging into a liquid nitrogen bath. The frozen sample was then pulverized into a

883   fine powder using a mixer miller MM 400 (Retsch). This powder was resuspended in 1

884   mL RAPPL lysis buffer and incubated for 15 mins, rotating end-over-end at 4□. The

885   lysates were clarified by centrifugation for 10 mins, 21,100 x g, 4□. Lysates were

886   transferred to a new tube and centrifugated again for 5 mins, 21,100 x g, 4□. Lysates

887   were then applied to 100 µL polylysine magnetic beads (Molecular Cloning

888   Laboratories) for 15-30 minutes at 4□, rotating. Beads were removed from the flow-

889   through by a magnet. The beads were washed three times with 250 µL RAPPL wash

890   buffer (100 mM HEPES·KOH solution, pH 7.5, 50 mM KCl, 10 mM Mg(OAc)$_2$, 1 mM

891   DTT, Protease Inhibitors (Cell Signaling), 40 U/mL RNaseOUT, 20 U/mL Superas·IN™

892   RNase Inhibitor). Beads were then eluted with 50-200ul RAPPL elution buffer (100 mM

893   HEPES·KOH solution, pH 7.5, 50 mM KCl, 10 mM Mg(OAc)$_2$, 2 mg/mL poly-D-glutamic

894   acid (Sigma #4033), 1 mM DTT, Protease Inhibitors (Cell Signaling), 40 U/mL

895   RNaseOUT, 20 U/mL Superas·IN™ RNase Inhibitor) incubating for 15 mins at room

896   temperature or 4□ with rotation or agitation to maintain bead suspension.

897

898   **Tandem Purifications**

899   RAPPL eluates from lysates of non-induced and arabinose-induced *E. coli Bl21 (DE3)*

900   cells expressing 2xHA-TevC-eGFP were applied to 25µl of αHA magnetic beads for 2

901   hours at 4□, rotating. When noted, lysates and buffers included 50 µM chloramphenicol

902 (CHL). Beads were washed three times using RAPPL wash buffer. Beads were eluted

903 in 50 µL RAPPL wash buffer plus 1µl of TEV protease (TEV Protease His, Genscript)

904 overnight at 4⬜ rotating.

905

Cellular Fractionation - Cytoplasmic, mitochondrial, nuclear

907 Nuclear and cytoplasmic fractions of Flp-In™ T-REx™ 293 with engineered HA-tag in

908 uL-4 were separated according to the manual for NE-PER™ Nuclear and Cytoplasmic

909 Extraction Reagent (Thermo Scientific™). Ribosome enrichment in both cellular and

910 nuclear fractions was analyzed using western blot analysis and an antibody for the HA-

911 tag, as indicated above in the RAPPL section. Nuclear fraction separation was

912 confirmed using western blot analysis and probing with antibody for topoisomerase II β

913 (Thermo Fisher Scientific # A300-950A). Cytoplasmic and mitochondrial fraction

914 separation was done by rapid enrichment of mitochondria by a previously published

915 procedure (*52*). The mitochondrial enriched fraction was lysed using RAPPL lysis buffer,

916 and a standard RAPPL procedure was followed up for ribosome enrichment. Western

917 blot analyses confirmed the successful separation of cytoplasmic and mitochondrial

918 fractions and the enrichment of ribosomes in both fractions. Enrichment of cytoplasmic

919 ribosomes was analyzed using Flag-antibody for endogenously tagged uS-4-Flag 40S

920 ribosomal protein. In contrast, the mRPS35 antibody for mitochondrial ribosomal protein

921 S35 (Proteintech® Cat No. 16457-1-AP) was used for the enrichment of mitochondrial

922 ribosomes and separation of the mitochondrial fraction. RAPPL eluates from

923 cytoplasmic, nuclear, and mitochondrial fractions were further analyzed by TEM, as

924 were other RAPPL isolated samples.

925

RNA Quality Analysis

Agarose gel

928 Standard 2% agarose (w/V) gel electrophoresis using Tris-Acetate Buffer with the

929 addition of 0.5% Clorox bleach (*53*) was performed for the analysis of RAPPL isolated

RNA species from human cell cultures (HEK293, HeLa, and HDFs). 1kb and 100 base pair DNA ladder Quick Load® markers (NEB # N0468L and N0467L) and 6x Gel loading Dye (NEB #B7024S) were used for sample preparation and as controls. HeLa cell lysate from the 1-Step Human IVT Kit (Thermo Fisher Scientific #88882) and yeast tRNA (Thermo Fisher Scientific #AM7119) were used as controls for rRNA and tRNA species.

RNA Quality and Quantity Assessment

Total RNA was isolated from *E. coli* cultures using the RAPPL protocol. The RNA concentration and purity of the RNA were initially measured using a NanoDrop spectrophotometer (Thermo Fisher Scientific), and RNA integrity was further assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies). For Bioanalyzer analysis, 1 µL of RNA (approximately 50 ng/µL) was used per sample and mixed with 1 µL High Sensitivity RNA Screen Tape Sample Buffer 96.00 (Agilent, cat. # 5067-5570). ScreenTape Ladder (Agilent, cat. # 5067-5081) was thawed on ice, mixed gently by flicking or vortexing at low speed, and briefly centrifuged to collect contents. The ladder and the sample are denatured at 72C for 3 min and placed on ice for 2 min. A new High Sensitivity RNA ScreenTape (Agilent, cat. # 5067-5579) was inserted into the TapeStation system (Agilent technologies 4200 TapeStation, 2200 TapeStation Controller Software), and 2 µL of each RNA sample was loaded into the corresponding wells of the sample plate. The TapeStation software was then used to initiate the High Sensitivity RNA analysis protocol. Samples were automatically processed, and the software generated quality, quantity, and sizing data.

Polysome Profiling

For polysome profiling, equal numbers of Hek T-RExTM-293 cells (R71007, Thermo Fisher) were plated and 24 hours later were treated with 100 µg/ml cycloheximide for 15 min before harvesting. A total of 6×10^6 cells were lysed in 500 µL of polysome lysis buffer (10 mM HEPES pH 7.4, 100 mM KCl, 5 mM MgCl2, 1 mM DTT, 1% NP-40, 100 µg/mL cycloheximide, 1X protease inhibitor cocktail, 25 U/mL DNase I, and 20 U/mL

959   RNase Inhibitor) on ice for 15 min before clearing at 13,000 rpm for 10 min at 4 °C. 1.5

960   mg of the lysate was layered over a 5–50% sucrose gradient (20 mM HEPES, 200 mM

961   KCl, 10mM MgCl2, 1 mM DTT, 100 µg/mL cycloheximide) (BioComp, gradient master

962   108) and subjected to centrifugation at 35,000 rpm for 2.5 hr at 4 °C using a SW41Ti

963   rotor (Beckman). The polysome profile in sucrose gradients was resolved using a

964   Brandel gradient fractionator. Absorbance was followed at 254 nm (Brandel UA-6).

965   Fractions were pooled and subjected to RAPPL.

966

967   ***In Vitro* Translation Assays**

968   *End-point*

969   All *E. coli in vitro* translation experiments with RAPPL purified ribosomes were

970   performed using New England Biolabs (NEB) PURExpress D Ribosome Kit (NEB

971   #E3313S) and New England Biolabs PURExpress In Vitro Protein Synthesis Kit (NEB

972   #E6800). All *E. coli in vitro* translation experiments used a DNA template created using

973   PCR to amplify the eGFP gene-containing region of a recombinant plasmid containing

974   the eGFP target protein in a pBAD vector. As in accordance with the NEB PURExpress

975   protocol   (https://www.neb.com/en-us/-

976   /media/nebus/files/manuals/manuale6800_e3313_e6840_e6850.pdf?rev=ba7a388352b

977   a4d0fb8089268e1852843&hash=9576CB18CA6990DD5925500898ACFB69), the DNA

978   template contained the in-frame coding sequence for the target protein along with a

979   starting codon, stop codon, T7 promoter sequence upstream of the target protein,

980   ribosome binding site upstream from translation region, a spacer region 6 base pairs

981   downstream from the stop codon, and a T7 terminator sequence downstream of the

982   stop codon. A pBAD specific T7 forward primer and pBAD specific polyA tail reverse

983   primer were used for all PCR amplification reactions (T7 forward primer used for

984   amplification   was   5'

985   TAATACGACTCACTATAGGGAGAAATAATTTTGTTTAACTTTAAGAAGGAG 3', and

986   the   pBAD   specific   reverse   primer   used   for   amplification   was   5'

987   TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAAACTCAATGGTGATGGTG

988   3'). All PCR reactions to create the DNA template were performed using NEB's

989 Phusion-HF polymerase kit (M0530S). All PCR products were analyzed on 1% agarose
990 gels and purified using Zymo Research's Zymoclean Gel DNA Recovery Kit (catalog #
991 11-301).

992 All reactions were assembled on ice and in accordance with NEB's protocol for the kit.
993 All recommended concentrations of solutions and reagents was followed for all
994 experiments unless otherwise stated, so all reactions (except for on-bead translation
995 experiments) were incubated at 37°C for 4 hours. On-bead translation experiments
996 were incubated in a table-top Thermomixer at 37°C and 850 RPM for 4 hours. Except
997 for the experiment testing ideal *in vitro* ribosome concentrations, 4.5 mL of RAPPL
998 purified ribosomes with concentrations averaging ~1.5 mg per mL were used for all
999 other experiments. Concentrations of RAPPL-purified ribosomes used for functional
1000 assays were determined by measuring absorbance at 260 nm using spectrophotometry
1001 (NanoDrop, Thermo Fisher Scientific). DNA template concentrations were consistent at
1002 150ng of eGFP template per reaction for all end-point experiments. Reactions with
1003 antibiotics present had antibiotics added immediately before 37°C incubation.

1004 After the 4-hour incubation, 2x sample buffer with 5% 2-Mercaptoethanol (Sigma
1005 Aldrich) was added to each reaction, and samples were boiled at 95°C for 5 minutes
1006 before being loaded onto SDS PAGE gels for western blot analysis. Equal amounts of
1007 samples were run on SDS PAGE gels (BIO-RAD 4-12% gradient Bis-Tris or XT Precast
1008 gels with catalog numbers mples were run on SDS PAGE gels (BIO-RAD 4-12%
1009 gradient Bis-Tris or XT Precast gels with catalog numbers #3450123 or #3450124)
1010 using XT MES running buffer (BIO-RAD). A semi-dry transfer of the SDS-PAGE gel
1011 was carried out using BIO-RAD's Immun-Blot PVDF membrane before the membrane
1012 with transferred protein was blocked in reconstituted (with PBS) 5% nonfat dry milk for 1
1013 hour (Research Products International). After blocking, the membrane with protein was
1014 incubated with 1:3000 diluted primary antibody overnight, washed with PBST (PBS plus
1015 0.1% Tween), and then incubated in 1:10000 diluted secondary antibody for 1 hour
1016 before imaging using chemiluminescence on a BIO-RAD ChemiDoc imaging system.
1017 Antibodies used for experiments include eGFP (Living Colors A.v. Monoclonal Antibody
1018 JL-8; catalog # 632381 and anti-mouse HRP-linked secondary antibody (Cell Signaling;
1019 catalog #7076).

1020

1021 *Kinetic Plate Assay*

1022 The DNA template for the kinetic plate *in vitro* assays of the RAPPL purified BL21(DE3)

1023 (Intact Genomics; catalog# 1051-24) *E. coli* ribosomes was created using the same

1024 process as the end-point assay DNA templates, and reactions were assembled on ice

1025 and in the same manner and concentrations as the end-point in vitro assays. A BioTek

1026 Cytation, 5 imaging reader, was used for all kinetic assays, and eGFP fluorescence was

1027 measured in 1-minute intervals for 2.5 hours in a 384 well plate at 37°C using relative

1028 fluorescence units with excitation settings at 488 +/- 9 and emission settings at 507 +/- 9

1029 with gain settings set to 122. The BL21 RAPPL purified ribosome replicates each had

1030 200 ng of eGFP tagged DNA template, and the negative control replicates had 0 ng of

1031 eGFP tagged DNA template--all other reaction conditions were kept the same between

1032 samples.

1033

1034 **Mass Spectrometry**

1035 The beads isolated after immunoprecipitation were incubated in 80 µL of buffer (2M

1036 urea, 50 mM tris (pH 7.5), 1 mM dithiothreitol, and 5 µg/mL trypsin (Promega: V511C))

1037 for 1 hour at 25C° and 1000 rpm to partially digest the proteins of the bead–generating

1038 an initial eluate. Two additional washes (2M urea, 50 mM tris (pH 7.5)) were performed

1039 to maximize yield. The initial eluate and washes were combined and clarified by

1040 spinning at 5000g.

1041 Following elution, half of the IP eluate was further reduced with 5mM DTT for 30 min at

1042 25C° and 1000 rpm, and alkylated in the dark with 10mM iodoacetamide for 45 min at

1043 25C° and 1000 rpm. For the flow-through (FT) and input samples (IN), 50ug of protein

1044 was reduced and alkylated under the same conditions. Samples were diluted with 50

1045 mM tris for a final urea concentration of < 2M. EDTA was added for a final concentration

1046 of 10 mM, followed by SDS to 1%.

1047 Magnetic SP3 beads were made by combining equal volumes of carboxylate-modified

1048 hydrophilic (Cytiva: 45152105050250) and hydrophobic beads (Cytiva:

1049   65152105050250). Each sample was used to resuspend 500 µg of SP3 beads. 100%
1050   ethanol was added to the sample at a 1:1 volumetric ratio to precipitate the protein
1051   material onto the beads. The samples were then incubated for 15 minutes at room
1052   temperature.

1053   Following incubation, the beads were washed thrice with 1 mL of 80% ethanol and
1054   reconstituted in 100 µL of freshly prepared ammonium bicarbonate with 0.5 µg of
1055   trypsin. The samples were incubated overnight at 37°C and 700 rpm to digest the
1056   proteins of the SP3 beads. Tryptic peptides were dried in a vacuum concentrator and
1057   resuspended in 3% acetonitrile/0.2% formic acid for a final 0.25 µg/µL peptide
1058   concentration.

1059   <u>LC-MS/MS analysis on a Q-Exactive HF</u>

1060   Approximately 1 µg of total peptides were analyzed on a Waters M-Class UPLC using a
1061   15 cm x 75 µm IonOpticks C18 1.7 µm column coupled to a benchtop Thermo Fisher
1062   Scientific Orbitrap Q Exactive HF mass spectrometer. Peptides were separated at a 400
1063   nL/min flow rate with a 90-minute gradient, including sample loading and column
1064   equilibration times. Data were acquired in data-dependent mode using Xcalibur
1065   software; each cycle's 12 most intense peaks were selected for MS2 analysis. MS1
1066   spectra were measured with a resolution of 120,000, an AGC target of 3e6, and a scan
1067   range from 300 to 1800 m/z. MS2 spectra were measured with a resolution of 15,000,
1068   an AGC target of 1e5, a scan range from 200–2000 m/z, and an isolation window width
1069   of 1.6 m/z.

1070   Raw data were searched against the Homo sapiens and Escherichia coli proteomes
1071   (UP000005640 and UP000000625, respectively) with MaxQuant (v2.6.3.0). The ppm of
1072   a protein's iBAQ value was calculated to determine protein enrichment within a sample.
1073   This was done by dividing a protein's intensity by the sum of all protein intensities in the
1074   respective sample and multiplying the resulting fractional value by 1,000,000. After that,
1075   a pseudocount of +1 was applied before the ppm values were log2-transformed. The
1076   log2 values were used to assign each protein a rank within its sample, serving as a. The
1077   iBAQ ppm, log2 values, and rank were subsequently used as indicators for protein
1078   enrichment within a sample.

Transmission Electron Microscopy

For analyses of ribosome preparations, samples were allowed to absorb onto freshly glow discharged formvar/carbon-coated copper grids (200 mesh, Ted Pella Inc., Redding, CA)) for 10 min. Grids were then washed two times in dH2O and stained with 1% aqueous uranyl acetate (Ted Pella Inc.) for 1 min. Excess liquid was gently wicked off, and grids were allowed to air dry. Samples were viewed on a JEOL 1200EX transmission electron microscope (JEOL USA, Peabody, MA) with an AMT 8-megapixel digital camera (Advanced Microscopy Techniques, Woburn, MA).

Cryo-EM

Grid preparation: RAPPL samples were applied to holey carbon, carbon-coated (2 nm thickness) Quantifoil R2/2 300 mesh grids that had been glow-discharged for 15s using an EMS GloQube Glow Discharger, which were then blotted for 2.5s at 4□ in 100% humidity. Samples were then vitrified by plunging into liquid ethane and cooled with liquid nitrogen using the Mark IV Vitrobot (FEI, Hillsboro, Oregon). Vitrified samples on grids were stored in liquid nitrogen prior to imaging. Data were collected on a Titan Krios G3 300 kV electron microscope (Thermo Fisher Scientific) with a sample auto-loading system, Cs Aberation Corrector, Volta Phase Contrast System, and STEM detector operating at 300 kV using a with Falcon IV Direct Electron Detection camera. Images were collected with the automated data collection software EPU 3 and processed on-the-fly with cryoSPARC Live (Thermo Fisher Scientific). A total of 2,498 videos with a total dose of 55 e/Å^2 split over 50 fractions (individual dose: 1.1 e/Å^2 per fraction) at a nominal magnification of 59,000x with a calibrated pixel size of 1.122 Å. Data were collected with a defocus range of –0.6 to –2.0 μm.

Cryo-EM Image Processing and Reconstruction

All data processing was done using cryoSPARC (*54*). The collected framesets were corrected for beam-induced motion on-the-fly using cryoSPARC Live patch motion correction and averages of all 50 frames were used for image processing. The contrast transfer function parameters were determined using Patch CTF job. A total of 561,289

particles were automatically picked using the blob-based picker. Particles were extracted and sorted into 100 2D classes, and artefactual particles were removed. Curated particles were then used in template-based particle selection, yielding 646,683 particles, which were again sorted into 50 2D classes. The final curated 2D classes yielded 399,114 particles, which were used for Ab Initio 3D reconstruction with 3 classes. Non-artefactual classes were subject to non-uniform refinement. Masks for the 60S, 40S, and 40S heads were generated using ChimeraX v1.8 (*55*). These were used for focused refinements and particle subtraction. The resolutions reported were based on gold-standard Fourier shell correlation curves.

References:

1136   1.   E. B. Keller, P. C. Zamecnik, R. B. Loftfield, The role of microsomes in the incorporation of amino acids into proteins. *J Histochem Cytochem* **2**, 378-386 (1954).

1139   2.   G. E. Palade, A small particulate component of the cytoplasm. *J Biophys Biochem Cytol* **1**, 59-68 (1955).

1141   3.   M. W. Nirenberg, J. H. Matthaei, The dependence of cell-free protein synthesis in *E. coli* upon naturally occurring or synthetic polyribonucleotides. *Proceedings of the National Academy of Sciences* **47**, 1588-1602 (1961).

1144   4.   N. Ban, P. Nissen, J. Hansen, P. B. Moore, T. A. Steitz, The complete atomic structure of the large ribosomal subunit at 2.4 A resolution. *Science* **289**, 905-920 (2000).

1147   5.   P. B. Moore, T. A. Steitz, The structural basis of large ribosomal subunit function. *Annu Rev Biochem* **72**, 813-850 (2003).

1149   6.   C. J. Shoemaker, R. Green, Translation drives mRNA quality control. *Nat Struct Mol Biol* **19**, 594-601 (2012).

1151   7.   D. N. Wilson, J. H. Doudna Cate, The structure and function of the eukaryotic ribosome. *Cold Spring Harb Perspect Biol* **4**, (2012).

1153   8.   J. A. Doudna, V. L. Rath, Structure and function of the eukaryotic ribosome: the next frontier. *Cell* **109**, 153-156 (2002).

1155   9.   S. Melnikov *et al.*, One core, two shells: bacterial and eukaryotic ribosomes. *Nat Struct Mol Biol* **19**, 560-567 (2012).

1157   10. J. P. Armache *et al.*, Cryo-EM structure and rRNA model of a translating eukaryotic 80S ribosome at 5.5-A resolution. *Proc Natl Acad Sci U S A* **107**, 19748-19753 (2010).

1160   11. M. M. Yusupov *et al.*, Crystal structure of the ribosome at 5.5 A resolution. *Science* **292**, 883-896 (2001).

1162   12. T. M. Schmeing, V. Ramakrishnan, What recent ribosome structures have revealed about the mechanism of translation. *Nature* **461**, 1234-1242 (2009).

1164   13. A. Korostelev, S. Trakhanov, M. Laurberg, H. F. Noller, Crystal structure of a 70S ribosome-tRNA complex reveals functional interactions and rearrangements. *Cell* **126**, 1065-1077 (2006).

14. A. Brown *et al.*, Structure of the large ribosomal subunit from human mitochondria. *Science* **346**, 718-722 (2014).

15. Y. Hashem *et al.*, High-resolution cryo-electron microscopy structure of the Trypanosoma brucei ribosome. *Nature* **494**, 385-389 (2013).

16. Q. Vicens, A. Bochler, A. Jobe, J. Frank, Y. Hashem, Interaction Networks of Ribosomal Expansion Segments in Kinetoplastids. *Subcell Biochem* **96**, 433-450 (2021).

17. F. Waltz, P. Giege, Striking Diversity of Mitochondria-Specific Translation Processes across Eukaryotes. *Trends Biochem Sci* **45**, 149-162 (2020).

18. N. M. Luscombe, R. A. Laskowski, J. M. Thornton, Amino acid-base interactions: a three-dimensional analysis of protein-DNA interactions at an atomic level. *Nucleic Acids Res* **29**, 2860-2874 (2001).

19. A. Trauner, M. H. Bennett, H. D. Williams, Isolation of bacterial ribosomes with monolith chromatography. *PLoS One* **6**, e16273 (2011).

20. A. M. Munoz *et al.*, Active yeast ribosome preparation using monolithic anion exchange chromatography. *RNA Biol* **14**, 188-196 (2017).

21. C. François *et al.*, The Utilization of Linear Polylysine Coupled with Mechanic Forces to Extract Microbial DNA from Different Matrices. *Microorganisms* **8**, (2020).

22. G. Liu *et al.*, Biological Properties of Poly-l-lysine-DNA Complexes Generated by Cooperative Binding of the Polycation * 210. *Journal of Biological Chemistry* **276**, 34379-34387 (2001).

23. A. D. Frank DeRosa, Shrirang Karve, Michael Heartlein. (Translate Bio Inc, USA, 2017), vol. US9850269B2.

24. M. Gorzkiewicz *et al.*, Poly(lysine) Dendrimers Form Complexes with siRNA and Provide Its Efficient Uptake by Myeloid Cells: Model Studies for Therapeutic Nucleic Acid Delivery. *International Journal of Molecular Sciences* **21**, 3138 (2020).

25. A. Gagarinova *et al.*, Systematic Genetic Screens Reveal the Dynamic Global Functional Organization of the Bacterial Translation Machinery. *Cell Rep* **17**, 904-916 (2016).

26. M. Jiang *et al.*, The Escherichia coli GTPase CgtAE is involved in late steps of large ribosome assembly. *J Bacteriol* **188**, 6757-6770 (2006).

27. P. Fuentes *et al.*, The 40S-LARP1 complex reprograms the cellular translatome upon mTOR inhibition to preserve the protein synthetic capacity. *Sci Adv* **7**, eabg9275 (2021).

28. A. Brown, M. R. Baird, M. C. Yip, J. Murray, S. Shao, Structures of translationally inactive mammalian ribosomes. *Elife* **7**, (2018).

29. C. Ribaut *et al.*, Concentration and purification by magnetic separation of the erythrocytic stages of all human Plasmodium species. *Malar J* **7**, 45 (2008).

30. E. M. Bunnik *et al.*, Polysome profiling reveals translational control of gene expression in the human malaria parasite Plasmodium falciparum. *Genome Biol* **14**, R128 (2013).

31. Y. Shimizu *et al.*, Cell-free translation reconstituted with purified components. *Nature Biotechnology* **19**, 751-755 (2001).

32. Z. Zou *et al.*, E. coli catheter-associated urinary tract infections are associated with distinctive virulence and biofilm gene determinants. *JCI Insight* **8**, (2023).

33. R. Edgar, E. Bibi, MdfA, an Escherichia coli multidrug resistance protein with an extraordinarily broad spectrum of drug recognition. *J Bacteriol* **179**, 2274-2280 (1997).

34. Ding, Zhu. (2012).

35. C. Orelle *et al.*, Tools for characterizing bacterial protein synthesis inhibitors. *Antimicrob Agents Chemother* **57**, 5994-6004 (2013).

36. C. Orelle *et al.*, Protein synthesis by ribosomes with tethered subunits. *Nature* **524**, 119-124 (2015).

37. Y. S. Polikanov *et al.*, Distinct tRNA Accommodation Intermediates Observed on the Ribosome with the Antibiotics Hygromycin A and A201A. *Mol Cell* **58**, 832-844 (2015).

38. E. A. Syroegin *et al.*, Structural basis for the context-specific action of the classic peptidyl transferase inhibitor chloramphenicol. *Nat Struct Mol Biol* **29**, 152-161 (2022).

1228   39.   T. C. Santiago, R. Zufferey, R. S. Mehra, R. A. Coleman, C. B. Mamoun, The
1229   Plasmodium falciparum PfGatp is an Endoplasmic Reticulum Membrane Protein
1230   Important for the Initial Step of Malarial Glycerolipid Synthesis*. *Journal of*
1231   *Biological Chemistry* **279**, 9222-9232 (2004).

1232   40.   A. Ferrari, S. Del'Olio, A. Barrientos, The Diseased Mitoribosome. *FEBS Lett*
1233   **595**, 1025-1061 (2021).

1234   41.   J. R. Warner, The economics of ribosome biosynthesis in yeast. *Trends Biochem*
1235   *Sci* **24**, 437-440 (1999).

1236   42.   S. Granneman, S. J. Baserga, Ribosome biogenesis: of knobs and RNA
1237   processing. *Exp Cell Res* **296**, 43-50 (2004).

1238   43.   A. Heuer *et al.*, Cryo-EM structure of a late pre-40S ribosomal subunit from
1239   Saccharomyces cerevisiae. *Elife* **6**, (2017).

1240   44.   G. E. Fox, Origin and evolution of the ribosome. *Cold Spring Harb Perspect Biol*
1241   **2**, a003483 (2010).

1242   45.   W. Trager, J. B. Jensen, Human malaria parasites in continuous culture. 1976. *J*
1243   *Parasitol* **91**, 484-486 (2005).

1244   46.   A. S. Nasamu *et al.*, Plasmepsins IX and X are essential and druggable
1245   mediators of malaria parasite egress and invasion. *Science* **358**, 518-522 (2017).

1246   47.   T. Nessel *et al.*, EXP1 is required for organisation of EXP2 in the intraerythrocytic
1247   malaria parasite vacuole. *Cell Microbiol* **22**, e13168 (2020).

1248   48.   S. Mukherjee, A. S. Nasamu, K. C. Rubiano, D. E. Goldberg, Activation of the
1249   Plasmodium Egress Effector Subtilisin-Like Protease 1 Is Mediated by
1250   Plasmepsin X Destruction of the Prodomain. *mBio* **14**, e0067323 (2023).

1251   49.   P. Olias, R. D. Etheridge, Y. Zhang, M. J. Holtzman, L. D. Sibley, Toxoplasma
1252   Effector Recruits the Mi-2/NuRD Complex to Repress STAT1 Transcription and
1253   Block IFN-γ-Dependent Gene Expression. *Cell Host Microbe* **20**, 72-82 (2016).

1254   50.   K. M. Brown, S. Long, L. D. Sibley, Conditional Knockdown of Proteins Using
1255   Auxin-inducible Degron (AID) Fusions in Toxoplasma gondii. *Bio Protoc* **8**,
1256   (2018).

51. R. Xu, W. L. Beatty, V. Greigert, W. H. Witola, L. D. Sibley, Multiple pathways for glucose phosphate transport and utilization support growth of Cryptosporidium parvum. *bioRxiv*, (2023).

52. B. Dixit, S. Vanhoozer, N. A. Anti, M. S. O'Connor, A. Boominathan, Rapid enrichment of mitochondria from mammalian cell cultures using digitonin. *MethodsX* **8**, 101197 (2021).

53. P. S. Aranda, D. M. LaJoie, C. L. Jorcyk, Bleach gel: a simple agarose gel for analyzing RNA quality. *Electrophoresis* **33**, 366-369 (2012).

54. A. Punjani, J. L. Rubinstein, D. J. Fleet, M. A. Brubaker, cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nature Methods* **14**, 290-296 (2017).

55. E. F. Pettersen *et al.*, UCSF ChimeraX: Structure visualization for researchers, educators, and developers. *Protein Sci* **30**, 70-82 (2021).

Figure legends

Fig. 1: The RAPPL method. A. Schematic describing the advantages of RAPPL over conventional methods. **B.** 2% agarose gel of RAPPLE purified RNA samples from of HEK-293 (HEK), human dermal fibroblasts (HDF) and HeLa human cell cultures. RNA isolated from commercial HeLa cell lysate (Con; Thermo Fisher HeLa IVT kit) and purified yeast tRNAs (tRNA, Ambion) were loaded as controls. NEB 100 bp and 1 Kb base pair markers (M1 and M2, respectively) are used to estimate size of isolated RNAs. **C.** Western blot analysis of HEK-293 lines uL4-HA and uS13-Flag tagged by CRISPR/Cas9 throughout the RAPPL purification process – lysate (Lys), flow-through (FT), wash (W) and elution (E1 and E2). RAPPL is selective for ribosome-associated factors, showing that the HA-tagged ribosomal protein uL4, Flag-tagged uS13, as well as the untagged uS9 are in the elution fractions. Translation factors are also enriched and purified by RAPPL as seen by the visualization of eIF3A and eIF4A1 proteins by specific antibodies in elution fractions. Presence of GAPDH, as a control for loading is detected in lysate and flow-through. Molecular markers indicate size of detected proteins. **D.** (top) Plot of the of each HEK-293 ribosomal protein's rank percentile in

relation to total protein rank percentile for each replicate of input, flow-through (FT), and bead-bound (IP) fractions. (bottom) Graph representing percentage of ribosomal proteins in total protein associated with input, flow-through (FT), and poly-lysine bead-bound (IP) fractions. Error bars represent standard deviation of triplicate averages.

Fig. 2: RAPPL can enrich and purify ribosomes from limited biological material. A. TEM visualization of RAPPL eluates from PureExpress® ribosomes from a 10-fold dilution scheme of 13.3 µM to 1.3 nM. The scale bar represents 500 nm. **B.** Western blot analysis using αHA antibody on RAPPL eluates of HEK-293 cells in which uL4 was HA-tagged by CRISPR/Cas9 whereby the starting cells were diluted to 1×10^6, 5×10^5, 2.5×10^5, 1×10^5, 5×10^4, 2.5×10^4, 1×10^4, 5×10^3, 1×10^3, and 0.1×10^3 cells prior to lysis. **C.** Western blot analysis using αHA antibody on RAPPL eluates of *P. falciparum* NF54 cells in which PfRACK was C-terminally tagged with mNeonGreen-HA whereby the starting cells were diluted to 5×10^7, 1×10^7, 5×10^6, and 1×10^6 cells. Molecular markers indicate size of detected proteins.

Fig. 3: RAPPL is a versatile method multiple single celled organisms, tissues, and multicellular organisms. A. TEM visualization of RAPPL eluates purified from several single celled organisms: *E. coli*, *S. cerevisiae*, *T. gondii*, *P. falciparum*, *C. parvum*. **B.** TEM visualization of RAPPL eluates purified from mouse tissue sections of spleen and liver as well as whole organisms *D. rerio* and *C. elegans*. **C.** TEM visualization of compartment-specific ribosomes generated from RAPPL eluates of cytoplasmic, mitochondrial, and nuclear (ribosome biogenesis) fractions. The scale bar represents 100 or 500 nm.

Fig. 4: The elutions of RAPPL can be used in downstream applications. A. HEK-293 lysates were treated with cycloheximide, anisomycine, and harringtonine with untreated lysate as a control. Ribosomes were purified using RAPPL in the presence of inhibitors and the eluates visualized by TEM. **B.** HEK-293 lysates were fractionated

1316 using polysome profiling. Fractions corresponding to ribosome subunit and monosomes,

1317 light polysomes, and heavy polysomes were pooled, respectively. These pools were

1318 diluted 1:5 to ensure that sucrose did not interfere with binding. The diluted, pooled

1319 samples were subject to RAPPL and the eluates visualized by TEM. **C.** Schematic of

1320 arabinose-inducible reporter expressing a 2xHA affinity tagged eGFP reporter

1321 separated by a TEV protease cleavage site (top). RAPPL was performed on bacterial

1322 lysates in the absence or presence of bacterial translation elongation inhibitor

1323 chloramphenicol (CHL) followed by αHA magnetic bead purification, again ±CHL, finally

1324 eluting with TEV protease. Eluates were visualized by TEM. Non-induced are shown as

1325 controls for lack of protein production and subsequent non-specific binding to αHA

1326 beads. The scale bar represents 500 nm.

1327

1328 **Fig. 5: RAPPL isolated ribosomes are translationally active and can be used for**

1329 **clinical applications. A.** Ribosomes were purified by RAPPL from *E. coli* DH5α cells

1330 grown to exponential phase, eluting in 30 µL of RAPPL elution buffer. Eluates were then

1331 used in the PURExpress® *in vitro* translation system instead of kit ribosomes. A PCR

1332 product encoding for eGFP harboring the T7 promoter and a polyA tail was used in the

1333 reaction (See Method for full details). Reactions were incubated for four hours.

1334 Ribosomes purified using RAPPL are active and able to translation mRNA. **B.** Activity of

1335 RAPPL purified E. coli BL21 ribosomes in the in vitro PURExpress® assays were

1336 observed using a kinetics protocol measuring eGFP fluorescence on an imaging plate

1337 reader. Relative fluorescence was determined with excitation settings set to

1338 wavelengths of 488 ± 9 and emission settings set to wavelengths of 507 ± 9. The

1339 standard deviation of technical triplicates eGFP fluorescence activity over a two hours

1340 and 30 minutes period with and without the DNA template encoding for eGFP are

1341 shown on the graph. **C.** Plate bacterial growth assays were performed using

1342 erythromycin (ERY), kanamycin (KAN), chloramphenicol (CHL), and clindamycin (CLI)

1343 to demonstrate strain resistance with LB only as controls for growth and the DH5α strain

1344 was used as a control strain. Concentration of used antibiotics is indicated. **D.** Synthesis

1345 of eGFP reporter by RAPPL isolated ribosomes in the absence and presence of

1346   indicated antibiotics (ERY, KAN, CHL, and CLI) targeting *E. coli* ribosomes. For each

1347   strain, 4.5 µL of 1.5 µg / µL of RAPPL isolated ribosomes was used for standard 25 µL

1348   PURExpress® *in vitro* Δ ribosome translation reaction (See Method for full details).

1349   Western blot analysis was performed on samples collected after 4 hours of incubation at

1350   37°C and visualized using αGFP specific antibody. Molecular markers indicate size of

1351   eGFP protein.

1352

1353   **Fig. 6: Structural determination of RAPPL products can produce high-resolution**

1354   **CryoEM Maps.** *C. neoformans* cells ($\sim10^8$) in exponential phase were lysed and the

1355   clarified lysate used in RAPPL. The ribosomes were eluted in 30 µL of elution buffer.

1356   The Eluate was first screened using TEM. Subsequently, grids were prepared using 5

1357   µL of eluate. Movies were captured on FEI Titan Krios G3 300kV Cryo-TEM with Falcon

1358   IV Direct Electron Detection camera. Data was processed using cryoSPARC resulting in

1359   an ~2.7 Å global resolution.

1360

Figure 1

Figure 2

A

13.3 μM

1.3 μM

500 nm

13.3 nM

1.3 nM

500 nm

B

kDa	Lys	1x10⁶	x10⁵			x10⁴			x10³			
			5	2.5	1	5	2.5	1	5	1	0.1	
75												
50												uL4-HA
37												

C

kDa	Lys	5x10⁷	1x10⁷	5x10⁶	1x10⁶	
100						
75						
60						PfRACK1-mNeonGreen-HA
45						

Figure 3

A

E. coli

S. cerevisiae

T. gondii

P. falciparum

C. parvum

B

Mouse

Spleen   Liver

D. rerio

C. elegans

C

HEK 293
(*H. sapiens*)

Cytoplasmic ribosomes   Mitochondrial ribosomes   Ribosome biogenesis (nuclear)

Figure 4

A

HEK 293
(H. sapiens)

Control	Cycloheximid	Anisomycin	Harringtonin

B

HEK 293
(H. sapiens)

Subunits & Monosomes	Light Polysomes	Heavy Polysomes

C

pBAD	2xHA	TevC	eGFP

RAPPL > elution > αHA-beads binding > wash > TEV cleavage > TEM

E. coli

Non-induced (control)	Induced	Induced + CHL

Figure 5

A

DH5α RAPPL ribosomes

kDa   0   1   2.5   4.5μl

eGFP

37
25
20

B

eGFP *in vitro* fluorescence of RAPPL
purified *E. coli* BL21 ribosomes

BL21 Negative
Control (No DNA)

BL21 Replicates
(eGFP DNA)

Relative Fluorescence Units
507+/-9 (RFU)

55,000
40,000
25,000
10,000
-5,000

0:30:00 0:45:00 1:00:00 1:15:00 1:30:00 1:45:00 2:00:00 2:15:00 2:30:00

Time Elapsed (HH:MM:SS)

C

[100 mg/mL ERY]   [12.5 mg/mL KAN]

Ec13
Ec24
A1408G
A2058G
DH5α

LB Only

Ec13
Ec24
A1408G
A2058G
DH5α

[12.5 mg/mL] CHL   [100 mg/mL CLI]

Ec13
Ec24
A1408G
A2058G
DH5α

D

kDa   No Antibiotic   5uM ERY
37
25
20
     Ec13 Ec24 A1408G A2058G   Ec13 Ec24 A1408G A2058G

kDa   No Antibiotic   1.5uM KAN   2uM KAN
37
25
20
     Ec13 Ec24 A1408G A2058G   Ec13 Ec24 A1408G A2058G   Ec13 Ec24 A1408G A2058G

kDa   No Antibiotics   50uM CHL
37
25
20
     Ec13 Ec24 A1408G A2058G   Ec13 Ec24 A1408G A2058G

kDa   No Antibiotics   50uM CLI
37
25
20
     Ec13 Ec24 A1408G A2058G   Ec13 Ec24 A1408G A2058G

Figure 6

RAPPL
60 mins

Ribosomes

Grid Preparation & Negative Staining

TEM Imaging

Grid Preparation

CryoEM Imaging

Processing

40S Head

2.7Å

40S

60S